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Abstract 
Renal transplantation (RTx) has become an established treatment modality for end-stage 
renal disease (ESRD). Along with the improvements in pre- and post-transplant (Tx) care, 
the patient and graft outcomes have improved significantly during the past two decades. 
This attracts more attention to avoiding secondary complications and long-term side 
effects of the post-Tx immunosuppressive medication. Several risk factors cast a shadow 
over patients’ normal physical and mental development, and quality of life, but detailed 
reports on long-term outcome after pediatric RTx are scarce. 
 
This thesis was designed to investigate pubertal development and subsequent male fertility 
and semen quality with special emphasis on the effects of immunosuppressive medication 
on reproductive function. The study also aimed to scrutinize metabolic risk factors and 
their consequences in patients after pediatric RTx. Analyses of the prevalence of 
metabolic syndrome and its components, as well as the effects of metabolic factors and 
blood pressure (BP) on kidney graft function were conducted. 
 
The study population included all 218 patients having undergone a pediatric RTx in 
Finland between 1979 and 2011. Background data were collected retrospectively from 
patient records. Cross-sectional data on bone age, testicular volume, and reproductive 
hormone levels were also gathered. Twenty-nine heart Tx (HTx) and 13 liver Tx (LTx) 
patients, and 56 healthy men served as controls in the BP and fertility studies, 
respectively. 
 
Data on 109 RTx recipients (72 males) were included in a two-part study consisting 
analyses on pubertal development and puberty-related reproductive hormone levels. The 
onset of pubertal development occurred at the mean age of 12.7 years in 55 boys with 22% 
considered delayed. In 29 girls, however, no delayed development occurred, with the age 
at onset of puberty and menarche averaging 10.7 years and 12.5 years, respectively. 
Pubertal growth continued relatively long resulting in acceptable final height (on average -
1.7 height standard deviation score in boys and -1.2 in girls). The serum levels of 
reproductive hormones assessed at the age of 8 to 21 years were normal in a great majority 
of the patients. 
 
The reproductive hormone levels and semen samples of 24 men were examined at a 
median of 18.6 years after RTx and the results were compared to those of 56 age-matched 
healthy men. The RTx recipients’ free testosterone levels were lower and LH levels were 
higher in comparison with their healthy peers (322 vs. 399 pmol/L, p = 0.001 and 7.6 vs. 
3.3 IU/L, p < 0.001, respectively). The RTx patients had smaller testicular volumes and 
total sperm counts than the controls (11.4 vs. 33.9 mL, p <0.001 and 1.3 vs. 135.5 million, 
p <0.001, respectively). Four men could not provide a semen sample and two refused. 
Only 4 out of 18 (22%) RTx men who provided a semen sample had normospermia. 
Patients with a history of cyclophosphamide therapy showed even worse outcome than 
those without. 
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Data on 210 RTx patients transplanted at a median age of 4.5 years were collected at 
several time points during a 13-year follow-up post-RTx. Serum lipid and glucose levels, 
weight, and BP results were correlated to the measured glomerular filtration rate (GFR). 
The mean decline of GFR after the first year of follow-up was 2.4 mL/min/1.73 m2/year. 
Hypertriglyceridemia associated with a lower GFR at 1.5 (p = 0.008) and 5 years post-
RTx (p = 0.017) and it predicted the subsequent GFR decline rate after 1.5 years post-
RTx. Beyond the first postoperative year, metabolic risk factors, except for triglycerides, 
associated modestly with the long-term kidney graft function in pediatric RTx patients. 
 
The ambulatory BP monitoring (ABPM) data on 111 renal, 29 heart, and 13 liver Tx 
recipients were retrospectively analyzed 5 to 10 years post-transplantation. The BP data 
were compared within the Tx groups and the BP profiles were found to be similar. The BP 
index and load were abnormal especially at nighttime and the nocturnal BP dipping was 
often blunted. The BP variables were equally valued when assessing hypertension. The 
use of antihypertensive medication did not notably change the ABPM profile in renal Tx 
recipients. BP load of 50% instead of 25% seems to be a more adequate cut-off value. The 
BP variables correlated poorly with the metabolic parameters or kidney graft function. 
 
In conclusion, our study shows that pubertal development was normal in all female and 
most of the male RTx patients. Testicular function was often impaired even years after 
RTx, and poor semen quality decreases the prospect of fertility in men after pediatric RTx. 
Metabolic risk factors had relatively little impact on the long-term kidney graft function. 
Hypertension is common, with emphasis on nocturnal prevalence, in Tx patients 
underlining the importance of the use of ABPM in diagnosing hypertension and in the 
follow-up. 
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Abbreviations 
ABPM ambulatory blood pressure monitoring 
ALG anti-lymphocyte globulin 
AR acute rejection 
ATG anti-thymocyte globulin 
BMI body mass index 
BP blood pressure 
CAN chronic allograft nephropathy 
CNI calcineurin inhibitor 
CsA cyclosporine A 
CNF congenital nephrotic syndrome of the Finnish type 
CVD cardiovascular disease 
EBV Epstein-Barr virus 
ESRD end-stage renal disease 
FH final height 
FSH follicle-stimulating hormone 
GFR glomerular filtration rate 
GH growth hormone 
GHbA1c glycosylated hemoglobin 
HDL high-density lipoprotein 
HRQOL health-related quality of life 
hSDS height standard deviation score 
HTx heart transplantation 
IGT impaired glucose tolerance 
LDL low-density lipoprotein 
LH luteinizing hormone 
LTx liver transplantation 
MP methylprednisolone 
MS metabolic syndrome 
OGS onset of growth spurt 
OGTT oral glucose tolerance test 
PHV peak height velocity 
PTLD post-transplant lymphoproliferative disorder 
RRT renal replacement therapy 
RTx renal transplantation 
SD standard deviation 
Tx transplantation 
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1 Introduction 
Renal transplantation (RTx) restores the ability of the body of a patient with end-stage 
renal disease (ESRD) to maintain water and acid-base balance, regulate electrolytes, 
excrete soluble wastes, and produce several hormones and enzymes. Since the beginning 
of RTx in the 1960s, the survival of ESRD patients had theoretically potential to increase, 
but the results during the early decades were suboptimal, mainly because of the lack of 
appropriate immunosuppression. The introduction of cyclosporine A (CsA) in the early 
1980s finally changed the setting from coping with the post-RTx complications to 
preservation of health by protecting the kidney graft from rejections (Starzl et al. 1982, 
Merion et al. 1984, Brodehl, Offner & Hoyer 1987). Along with the wider repertoire of 
immunosuppressive medication, the perioperative care improved and diagnosis and 
treatment of rejections and infections advanced, establishing RTx as a treatment of choice 
for ESRD patients. 
 
The first renal transplantations for adolescent patients in Finland were performed in the 
late 1960s, but the systematic pediatric RTx program started in 1986 at Children’s 
Hospital, Helsinki University Central Hospital. By March 2011, a total of 218 children or 
adolescents had received 245 kidney grafts in Finland. The number of pediatric renal 
transplantations has been on average 10 operations/year over the past decade. The 
incidence of renal replacement therapy (RRT) in children aged 0–14 years is 4.4 per 
million age-related population in Europe and 6.8 per million age-related population in 
Finland (ESPN/ERA-EDTA Registry 2013). According to this report, the prevalence of 
pediatric patients on RRT was 84.4 per million age-related population in Finland, being 
the highest in Europe. 
 
The function of the kidney graft may be impaired by both immunological and non-
immunological risk factors, such as acute and chronic rejections, infections, calcineurin 
inhibitor (CNI) toxicity, and metabolic complications. Cardiovascular disease (CVD) is 
known to be the leading cause of mortality in RTx patients (NAPRTCS 2010). Pediatric 
patients are bound to receive immunosuppressive therapy for decades, emphasizing the 
importance of good graft function and optimal drug therapy. 
 
Previous data suggest that, despite the catch-up growth occurring after pediatric RTx, the 
patients remain stunted and their pubertal development may be delayed. Due to the 
inevitable decrease in kidney graft function and life-long medication, especially CNIs and 
glucocorticoids, the patients are prone to diverse metabolic disorders. To date, long-term 
data on children transplanted in early childhood are scarce. This study was therefore 
carried out to study the endocrinologic and metabolic effects in the long run in pediatric 
RTx recipients. 
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2 Review of the literature 
2.1 Renal transplantation in children 
2.1.1 Indications 
The indications for pediatric RTx differ from those of adult patients, with emphasis on 
congenital and structural causes. Furthermore, the most common disease leading to 
pediatric RTx in Finland, the congenital nephrotic syndrome of the Finnish type (CNF), 
differentiates the age distribution of children undergoing RTx in Finland from all other 
international registry reports. Possibly due to a limited gene pool in the Nordic countries 
in comparison with the US for instance, the possibility of inherited disorders is increased; 
and the age at RTx is lower (Tyden and Berg 1998). Half of the Finnish patients are aged 
5 years or less at the time of index RTx, while the proportion of such young children in the 
US is currently 19% (Laine et al. 1994, NAPRTCS 2010). 
 
CNF is caused by a mutation in the NPHS1 gene, the gene product of which is called 
nephrin, a protein responsible for the connection of podocyte foot process to the 
glomerular capillary wall (Ruotsalainen et al. 1999). Two founder mutations occur, Fin-
major and Fin-minor, both leading to massive proteinuria during the first months after 
birth, with secondary consequences comprising hypoproteinemia, edema, oliguria, 
hyperlipidemia, hypothyreosis, and increased risk for infections and thrombotic 
complications (Holmberg et al. 2004). 
 
The second most common indication for pediatric RTx in Finland is posterior urethral 
valve. It is a congenital disorder in which urinary flow is obstructed by tissue membranes 
in male patients leading to bladder dysfunction and, on average, later to ESRD in 10% of 
the patients (Hennus et al. 2012). In order to avoid adverse effects on graft survival, the 
lower urinary tract should be reconstructed prior to RTx (Reinberg et al. 1988). The other 
indications for pediatric RTx in the Finnish and US populations are listed in Table 1. 
 
RRT is considered when renal insufficiency prevents the maintenance of body 
homeostasis and waste excretion. The actual indications for RRT depend on a combination 
of several biochemical and clinical characteristics, some of which may be managed with 
medications or dietary consulting (Greenbaum and Schaefer 2012, Warady, Morgenstern 
& Alexander 2004). Renal function assessment is obviously a critical part of the process, 
and the current consensus in the field of pediatric nephrology for the initiation of dialysis 
is when the glomerular filtration rate (GFR) falls below 10–15 mL/min/1.73 m2 
(Greenbaum and Schaefer 2012). 
 
 
 
 
 
12 
RRT is instituted in most children either by peritoneal or hemodialysis, or RTx. According 
to the European and North American registry reports, a fifth to a quarter of the patients 
undergo RTx pre-emptively, i.e., without prior dialysis (ESPN/ERA-EDTA Registry 
2013,  NAPRTCS 2010). About half of the kidney grafts in the US are from living related 
donors, whereas grafts from deceased donors have historically been used in Europe 
(Benfield et al. 1999). At our center, a sixth of the grafts during the last decade were of 
living related donor origin. This is a relatively higher proportion than in adult RTx but 
lower than in the pediatric RTx during the 1980’s and 1990’s in Finland (Mäkelä et al. 
2013, Tyden and Berg 1998). Even though RTx is accepted as the optimal treatment for 
ESRD it has some limitations. In case of active and progressing disease (such as hemolytic 
uremic syndrome or malignancy) RTx should be postponed until the underlying condition 
is stabilized. 
2.1.2 Histocompatibility and surgical aspects 
The ABO blood group compatibility is required in the Finnish RTx protocol. Human 
leukocyte antigen (HLA) typing is made for the donor and recipient candidates and the 
alleles used at the histocompatibility matching are HLA-A, -B, and -DR. The best, thus 
the least, mismatched pairs are chosen for the subsequent leukocyte cross-matching test in 
which a negative result is further required before proceeding to operation. Among the 
pediatric RTx in Finland, the mismatching results have been very good and 91% of the 
donors are 2/1 or less mismatched with their donor. Although the beneficial effect of 
minimizing the mismatches has been shown, even the zero-mismatched grafts such as any 
graft, may fail for several reasons (Duquesnoy 2007). 
 
The surgical procedure of RTx in children is performed in a similar manner as in adults, 
thus preferring the standard pelvic extraperitoneal placement (Vukcevic et al. 2007). In 
smaller children weighing less than 30 kg, individualized approach is advised, 
emphasizing the matching of blood vessel size and requirements of circulatory volume 
issues. Traditionally, intraperitoneal placement of the graft is used for children weighing 
less than 20 kg. According to our center’s experience an adult kidney graft can safely be 
placed extraperitoneally in children weighing over 10 kg (Laine et al. 1994). 
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Table 1. Indications for pediatric renal transplantation in Finland and North America. 
Primary disease Finland 
(n = 218) 
North America 
(n = 9 969) 
Hereditary disorders 54% (n = 117) 12% (n = 1 163) 
Congenital nephrotic syndrome 38% 3% 
Nephronophthisis 8% 3% 
Polycystic kidney disease 6% 3% 
Other 2% 3% 
Structural disorders 24% (n = 53) 41% (n = 4 128) 
Posterior urethral valve 12% 16% 
Renal aplasia/hypoplasia/dysplasia 7% 17% 
Reflux nephropathy 4% 6% 
Prune belly syndrome 2% 3% 
Other conditions 22% (n = 48) 47% (n = 4 678) 
Glomerulonephritis 6% 10% 
Vasculitides 2% 3% 
Hemolytic uremic syndrome 2% 3% 
Interstitial nephritis 1% 2% 
Miscellaneous* 11% 29% 
The Finnish and US data are between 1979–2011 and 1987–2010, respectively. US data were adapted from 
the NAPRTCS annual report (2010) after excluding patients with unknown diagnosis (n = 663). * Including 
focal segmental glomerulosclerosis (FSGS), which is the 3rd most common indication in the US. 
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2.1.3 Immunosuppression 
The recipient’s immune system becomes aware of the presence of an organ graft instantly 
after implantation and launches a response to destroy it as an alien intracorporeal agent, 
unless being blocked. Suppression of lymphocyte activity against the graft is thus an 
indispensable element of RTx and needs to be started perioperatively. Immunosuppressive 
agents cause immunodeficiency with the benefit of rejection suppression but the 
disbenefits of undesired effects, such as infections, cancer, and nonimmunologic toxicity. 
The basic goal of immunosuppressive drug therapy is, on one hand, to achieve the lowest 
level of immunosuppression to prevent rejection, and on the other hand, to avoid the side 
effects caused by overimmunosuppression, e.g. opportunistic infections and malignancies. 
This endless balancing with the optimal dosage remains the hallmark of 
immunosuppressive medication. 
 
In general, immunosuppression is attained by blocking pathways of lymphocyte response, 
diverting lymphocyte traffic, or depleting lymphocytes (Halloran 2004). At present, a 
multidrug combination therapy, most commonly by triple medication, is administered, 
targeting different steps of T-cell activation (Figure 1). Each drug has different modes of 
action, which are preferably utilized in a synergistic manner. This is helpful in maintaining 
the balance between rejection and overimmunosuppression; in other words, the use of 
multiple drugs allows the reduction of individual agents to a minimum without losing the 
efficacy, together with improving the means to tolerate dose-dependent drug toxicities 
(Denton, Magee & Sayegh 1999). Still, all the immunosuppressants have their own dose-
dependent adverse effects, which should be carefully followed and avoided. The 
favourable and the most common and clinically significant effects of immunosuppressants 
are listed in Table 2. 
 
Children metabolize medications at different rates from adults; tailored schedules and 
special formulations are thus characteristic for treating pediatric patients (Hoppu et al. 
1991, Bunchman et al. 2001, Seikku et al. 2006). The half-life of CsA, for example, has 
been shown to be shorter in children than in adults, thus requiring dosing three times daily 
rather than twice-daily which is common in adult recipients (Cooney, Habucky & Hoppu 
1997). 
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Figure 1. Targets for immunosuppressive agents in relation to the three-signal model of T-cell 
activation. Stimulation of T-cell receptor (TCR) with the major histocompatibility complex (MHC) class II 
molecule (signal 1) leads to the activation of the calcineurin pathway, a process inhibited by cyclosporine A 
and tacrolimus. Calcineurin pathway activation results in the induction of a number of cytokine genes, 
including interleukin-2 (IL-2). Glucocorticoids inhibit cytokine gene transcription in lymphocytes and 
antigen-presenting cells by several mechanisms. Costimulatory signals (signal 2) are necessary to T-cell IL-
2 gene transcription, prevention of T-cell anergy, and T-cell apoptosis inhibition. IL-2 receptor stimulation 
of the target lymphocyte (signal 3) induces the cell to enter cell cycle and proliferate, a process that may be 
blocked by anti-IL-2 receptor antibodies or by rapamycin. Following progression into cell cycle, 
azathioprine (Aza) and mycophenolate mofetil (MMF) interrupt DNA replication by inhibiting de novo 
purine synthesis. (Adapted from Lui 2001). 
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Table 2. Characteristics of immunosuppressive agents commonly used in organ transplantation. 
Immunosuppressant Mechanism of action Favorable effect Adverse effects 
Cyclosporine A Inhibition of IL-2 
gene transcription 
Decreased T-cell 
activation 
Nephrotoxicity, hirsutism, 
neurotoxicity, hypertension, 
dyslipidemia, gingival 
hyperplasia 
Tacrolimus Inhibition of IL-2 
gene transcription 
Decreased T-cell 
activation 
Nephrotoxicity, 
neurotoxicity, diabetes, 
hypertension, 
gastrointestinal toxicity 
Azathioprine Inhibition of de novo 
purine synthesis 
Inhibited T- and B-
lymphocyte 
proliferation 
Bone marrow suppression, 
hepatotoxicity, skin cancer 
Mycophenolate mofetil/ 
enterocoated 
mycophenolate sodium 
Inhibition of de novo 
purine synthesis 
Inhibited T- and B-
lymphocyte 
proliferation, cell 
adhesion, migration, 
and antibody 
formation 
Gastrointestinal toxicity, 
bone marrow suppression 
Sirolimus/everolimus Blocking of signals 
from cell surface 
receptors 
Inhibited 
differentiation and 
proliferation of 
lymphocytes, and 
stimulation of T-cell 
apoptosis 
Impaired wound healing, 
dyslipidemia, infertility, 
myalgia/arthralgia, oral 
ulcerations, acne 
Glucocorticoids Complex interaction 
with non-signaling 
and signaling 
proteins and 
receptors, inside and 
outside cells 
Reduced T-
lymphocyte activation 
and proliferation as 
well as suppressed 
antibody and complex 
binding 
Diabetes, hypertension, 
dyslipidemia, osteoporosis, 
impaired growth, weight 
gain, gastrointestinal 
toxicity, acne, adrenal 
dysfunction 
Anti-thymocyte globulin/ 
anti-lymphocyte globulin 
Polyclonal cytotoxic 
antibodies against T-
cell surface antigens 
Depleted count of 
circulating 
lymphocytes and 
inhibition of 
lymphocyte function 
Cytokine release syndrome, 
anaphylaxis, infections 
Basiliximab Interleukin 2 
receptor antibody 
Depleted count of T-
lymphocytes 
No substantial adverse 
effects 
OKT3 (muromonab-CD3) CD3 antibody Interrupted antigen 
recognition, T-cell 
signaling and 
proliferation 
Cytokine release syndrome 
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Calcineurin inhibitors (CNIs) CsA and tacrolimus inhibit T-lymphocyte activation and 
are the cornerstone of immunosuppression in the field of transplantation (Andreoni et al. 
2007). In brief, they bind to their specific cytoplasmic receptors (cyclophylin and FK-
binding protein 12, respectively) and the resulting complexes inhibit and inactivate 
calcineurin, a pivotal enzyme in T-cell receptor signaling (Clipstone, Crabtree 1992). 
Without the effect of calcineurin, translocation of nuclear factor of activated T 
lymphocytes (NFAT) from cytoplasm into the nucleus is impossible. NFAT, in turn, is 
needed for induction of interleukin-2 and other cytokine genes necessary for T-cell growth 
and differentiation (Kahan 1989). 
 
CNIs are known to be nephrotoxic (Kaplan, Schold & Meier-Kriesche 2003, Webster et 
al. 2005) and the cumulative effect of CsA and angiotensin-converting enzyme inhibitors 
or angiotensin II receptor blockers causing glomerular hypoperfusion may further 
exacerbate the deleterious effects (Kengne-Wafo et al. 2009). At first, the effect was 
suggested to be reversible, characterized by arteriolar vasoconstriction leading to 
decreased renal function (Klintmalm, Iwatsuki & Starzl 1981, Morris et al. 1983). Today, 
this effect is known as ”acute CNI nephrotoxicity”, but a greater problem is the 
irreversible renal dysfunction, ”chronic CNI nephrotoxicity” discovered later, 
characterized by glomerulosclerosis, interstitial fibrosis, and tubular vacuolization (Myers 
et al. 1984, Starzl et al. 1990). The CNI-related nephrotoxicity is one of the predominant 
non-immunological factors for chronic kidney dysfunction, but some changes attributed to 
chronic CNI toxicity may, however, be a consequence of immunologic injury (Gaston et 
al. 2010, Issa, Kukla & Ibrahim 2013). The spectrum of the adverse effects of CsA and 
tacrolimus resemble each other due to the similar immunosuppressive activity but, 
remarkably, the structural disparity paves the way for differences.  
 
Antiproliferative agents (antimetabolites) azathioprine, and mycophenolic acid (MPA; 
comprising mycophenolate mofetil, MMF and enterocoated mycophenolate sodium, EC-
MPS) interfere with de novo purine nucleotide synthesis and metabolism. As a 
consequence, DNA replication is prevented, blocking the differentiation and proliferation 
of alloactivated T- and B-lymphocyte clones. Azathioprine, a prodrug metabolized to 6-
mercaptopurine, was the first immunosuppressive agent approved for Tx use, but despite 
the wide experience, its mechanism of action remains ambiguous (Tiede et al. 2003). 
MMF and EC-MPS, in turn, are precursors of MPA, which acts by inhibiting inosine 
monophosphate dehydrogenase (IMPD), a key enzyme in de novo synthesis of guanosine 
mono phosphate (Eugui, Allison 1993). 
 
Antimetabolites have a relatively wide therapeutic window and rather well tolerated side 
effect profiles (Salvadori et al. 2004, Budde et al. 2004). MPA has thus largely replaced 
azathioprine worldwide (Denton, Magee & Sayegh 1999). The most common side effects 
of antimetabolites are bone marrow suppression and various gastrointestinal symptoms 
(Table 2). 
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Glucocorticoids are potent unspecific anti-inflammatory drugs with a substantial list of 
indications alongside the field of transplantation. The glucocorticoid receptor-mediated 
effects primarily target transcription factors, such as nuclear factor kappa beta (NF-κB) 
(Heck et al. 1994, McKay and Cidlowski 1999). Consequently, this inhibits synthesis of 
multiple cytokines by T cells and macrophages essential for T lymphocyte activation and 
tissue injury (Scheinman et al. 1995). The immunosuppressive mode of action is, 
however, immensely diverse due to additional glucocorticoid receptor-independent effects 
occurring at higher doses (Buckbinder, Robinson 2002). 
 
The downside of the polymorphic mode of action is the association with myriad 
deleterious effects, especially in long-term use. The list goes beyond those in Table 2: 
weight gain, cushinoid appearance, acne, skin fragility, sodium and fluid retention, aseptic 
bone necrosis, myopathy, cataracts, glaucoma, increased infection risk, impaired wound 
healing, and neuropsychiatric symptoms (such as depression, mania, psychosis, and 
insomnia) (Denton, Magee & Sayegh 1999, Bergmann et al. 2012). Not surprisingly, a 
long history of glucocorticoid withdrawal or avoidance exists in transplantation (Hricik et 
al. 1993). Despite the successful results of several studies (Rike et al. 2008, Pascual et al. 
2004), other reports have been concerned with increased risk for acute rejection (AR) 
(Chao et al. 1994, Ahsan et al. 1999). Probably due to the short-term nature of these 
reports and the lack of long-term prospective studies for confirming the conclusions, most 
centers worldwide still consider glucocorticoids as a fundamental adjunct to 
immunosuppression (Pascual 2011).  
 
The mammalian target of rapamycin (mTOR) inhibitors sirolimus (rapamycin) and its 
derivate everolimus are among the new antiproliferative immunosuppressive agents 
(Schuler et al. 1997). Rapamycin binds the same FK-binding protein 12 as tacrolimus, but 
the complex does not inhibit calcineurin. Instead, it inhibits the mTOR pathway by 
blocking IL-2 receptor-mediated signals from the cell surface, further inhibiting the 
proliferation of lymphocytes, mesenchymal cells, and tumor cells (Sehgal 2003).  
 
The adverse effect profile is wide: bone marrow toxicity (anemia, leukocytopenia, and 
thrombocytopenia), aggravated nephrotoxicity when combined with CNIs, 
hyperlipidemia, reduced testosterone levels, infertility, pneumonitis, and wound-healing 
problems (Meier-Kriesche et al. 2005, Fritsche et al. 2004, Gonwa et al. 2003, Boobes et 
al. 2010). 
 
Intravenously administered polyclonal antibodies, anti-lymphocyte or anti-thymocyte 
globulin (ALG/ATG), can be utilized against numerous surface antigens of T-cells 
resulting in depletion of circulating lymphocytes and inhibition of lymphocyte functions 
(Shield et al. 1997, Bonnefoy-Berard, Vincent & Revillard 1991). The major monoclonal 
antibodies in clinical use, basiliximab and daclizumab, exert their effect by targeting 
interleukin-2 receptor modulating T-cell functions and depleting T-lymphocytes from 
peripheral blood (Nashan et al. 1997, Ortho Multicenter Transplant Study Group 1985, 
Kahan, Rajagopalan & Hall 1999). OKT3 (muromonab-CD3) is rarely used today, mainly 
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for anti-rejection therapy with MP. It has a significant adverse effect, cytokine release 
syndrome, which may occur especially after the initial dose (Gaston et al. 1991). Pre-
treatment with antipyretics, antihistamines, and corticosteroids can be used to prevent 
these flu-like symptoms (fever, headache, diarrhea, nausea, bronchospasm, and 
fluctuations of blood pressure (BP)) (Goldman et al. 1989). 
 
The clinical protocols and regimens consist of three major therapeutic phases: induction, 
maintenance, and antirejection therapies (the last of which is addressed in detail in the 
rejection section below). The rejection risk after RTx is not spread evenly over time; in 
fact, the risk is significantly higher during the first six months post-Tx with a decreasing 
trend thereafter (Nankivell et al. 2003). The immunosuppressive therapy during the 
induction and early maintenance phases emphasizes the need for greater doses followed by 
reduction over time. During the continuous life-long maintenance treatment doses may be 
stable for long, but in case of an established rejection multiplied doses may be needed as a 
short-course therapy.  
 
Induction therapy is currently executed for the majority of pediatric RTx recipients by 
ALG, ATG, or anti-interleukin-2-receptor antibody basiliximab or daclizumab 
(NAPRTCS 2010). At our center basiliximab has been used since the year 2000 at 2 doses, 
intraoperatively and on the 4th post-RTx day. Children under 35 kg receive 10-mg doses 
while others receive 20-mg doses. The maintenance immunosuppressive is started 
perioperatively, the early maintenance therapy hence overlapping with the induction 
therapy. On the first postoperative day the CsA dose is 4.5 mg/kg and azathioprine dose is 
2 mg/kg, both divided into three doses, and methylprednisolone (MP) dose is 1.5 mg/kg, 
divided into two doses. 
 
The maintenance therapy protocol used at the study center is presented in Table 3. In 
brief, the first weeks post-RTx require attentive follow-up of CsA trough blood 
concentrations and adjustments of CsA dosage (usually 2–4(–6) mg/kg/day), respectively. 
During the first 12 months post-RTx CsA dose is gradually tapered to reflect a target 
trough blood concentration of 150 µg/L. When MP is switched to every-other-day dosing 
at 3–6 months post-RTx, the azathioprine dose is increased slightly. After the first post-
RTx year, CsA is individually targeted to a level of 80–120 µg/L and azathioprine dose to 
1.0–1.4 mg/kg/day. The MP daily dose is on average 0.06 mg/kg with no increase along 
patient’s growth. 
 
Tacrolimus is used instead of CsA after retransplantation or later in case of recurrent 
rejections, gradually increasing creatinine, or major cosmetic problems (hypertrichosis, 
gum hyperplasia). The typical maintenance therapy trough concentration is 5-7 mg/L. 
Azathioprine is replaced by a mycophenolate in case of recurrent rejections or gradually 
increasing creatinine. The usual maintenance dose is 500–1000 mg/day. Also, if CsA or 
tacrolimus toxicity is suspected, azathioprine can be switched to mycophenolate and the 
dosing of CsA or tacrolimus reduced. 
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Table 3. Initial protocol for immunosuppressive therapy used at the study center. 
Post-RTx time Cyclosporine A 
(trough concentration goal) 
Azathioprine 
(mg/kg/day) 
Methylprednisolone 
(mg/kg/day) 
First month 300 µg/L 1.0–2.0 0.25–1.0 
1–3 months 250–300 µg/L 1.0 0.25 
3–6 months 200–250 µg/L 1.0 0.25 
6–12 months 150–200 µg/L 1.4 0.3 e.o.d. 
>12 months   80–120 µg/L 1.0–1.4 0.1–0.2 e.o.d. 
E.o.d. every other day. Cyclosporine A is switched to tacrolimus and/or azathioprine is replaced by 
mycophenolate in case of recurrent rejections or gradually increasing creatinine. If calcineurin inhibitor 
toxicity is suspected, azathioprine is switched to mycophenolate and the dosing of cyclosporine A or 
tacrolimus is reduced. 
2.2 Complications 
2.2.1 Rejections 
Core needle biopsy is the gold standard for diagnosing varied rejectional and non-
rejectional lesions related to the allograft. The immunopathologic mechanisms of rejection 
are cell-mediated (caused by T-cells) and humoral (caused by antibodies), either alone or 
together (Cohen 2007). Cell-mediated AR occurs typically within the first 2 months post-
RTx but may rarely appear even years after engraftment. T-cells infiltrate the tubulo-
interstitium and arteries separately or together and the lesions may be patchy. Antibody-
mediated rejection (ABMR) is the result of donor-specific antibodies and can appear as 
hyperacute, acute humoral, and chronic rejection. Hyperacute rejection can be avoided by 
ensuring a negative result in crossmatch test screening for the recipient’s preformed 
antibodies against the donor’s HLA. ABMR is diagnosed by: 1. Identification of 
histological evidence of specific tissue injury, 2. Evidence of antibody interaction with 
vascular endothelium, and 3. Serologic evidence of donor-specific antibodies (HLA or 
other) (Haas et al. 2014). 
 
Historically, more than half of deceased organ recipients experienced an AR during the 
first post-RTx weeks. The majority of patients now experience an AR-free year and less 
than half of patients experience an AR episode at all (NAPRTCS 2010). Treatment of the 
cell-mediated AR is initiated by intravenous corticosteroid pulses, typically with 10–30 
mg/kg doses lasting for 3–5 consecutive days. In addition, augmentation of 
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immunosuppressive therapy is usually performed with a slow tapering of oral 
corticosteroids. Severe, recurrent, or steroid-resistant rejections are typically treated with 
ALG/ATG. Treatment of an ABMR may require use of plasmapheresis, intravenous 
immunoglobulins, cyclophosphamide, or rituximab (anti-CD-20 antibody) in addition to 
the aforementioned therapies (Montgomery et al. 2000). 
 
Chronic allograft nephropathy (CAN) in a kidney graft may occur as early as 3 months 
post-RTx and it typically develops over months to years. Clinically CAN is designated as 
gradual loss of renal function and the morphological changes occur in all components to 
varying degrees (Fletcher, Nankivell & Alexander 2009). Interstitial fibrosis and tubular 
atrophy (IF/TA), and prominent arterial and glomerular lesions may be seen in core needle 
biopsy samples (Sibley 1994). CAN accounts for a third of the graft failures in the 
NAPRTCS data, being the most common cause for graft loss (NAPRTCS 2010). On the 
other hand, Qvist et al. (2000) reported that two thirds of the patients having undergone an 
RTx under the age of 5 years had no signs of CAN in biopsy at 7 years post-RTx. 
2.2.2 Infections 
Advancements in immunosuppressive drugs have reduced the incidence of ARs but at the 
same time may have exacerbated the risk of infections post-RTx (Dharnidharka, Stablein 
& Harmon 2004). Within the first month post-RTx, infections are generally associated 
with donor- or recipient-derived pre-existing conditions or complications of surgery 
(Fishman 2007). The latter include bacterial wound infections, sepsis, urinary tract 
infections, and pneumonia. Between 1 and 6 months post-RTx, the nature of infections 
changes dramatically and viral infections are most common, either as a primary infection 
or a reactivation of viruses, paving way for other opportunistic infections as well (Green, 
Michaels 2007, Rubin 1993). Still, fungal infections are infrequent after RTx. Later on, in 
the 6- to 24-month post-RTx period, the percentage of hospitalization owing to viral 
infections has increased over time (Dharnidharka, Stablein & Harmon 2004). On the other 
hand, according to a Finnish study, upper respiratory tract infections are the most common 
problem in pediatric RTx recipients with a rate and severity similar to age-matched 
healthy children (Their et al. 2000). The study also reported severe bacterial infections 
being rare, but urinary tract infections were found in 39% of pediatric RTx patients. 
 
Immunomodulating viruses, especially cytomegalovirus and Epstein-Barr virus (EBV), 
are a major threat for RTx patients without prophylactic medication (Fishman 2007, Korn 
et al. 1992). Cytomegalovirus is a common and important cause for viral infection post-
RTx and without prophylaxis, a symptomatic disease typically manifests 1–3 months after 
transplantation (Green, Michaels 2007). A characteristic constellation of fever and 
hematological abnormalities (including leukopenia, atypical lymphocytosis and 
thrombocytopenia) is associated with cytomegalovirus disease and a disseminated disease 
may manifest by involvement of the gastrointestinal tract, liver, or lungs. The use of 
ganciclovir prophylaxis has, however, decreased the incidence and severity of 
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cytomegalovirus disease. The significance of EBV infections, especially in pediatric Tx 
where primary EBV infections are emphasized, has grown in parallel with recognition of 
mortality and morbidity related to EBV disease (Green et al. 1999). Careful diagnosing of 
EBV disease (by clinical, laboratory, and histopathologic examination) is important due to 
the ominous post-transplant lymphoproliferative disorders (PTLD) (see below). 
 
Polyomaviruses BK and JC have been identified in association with nephropathy in RTx 
recipients (Fishman 2007). BK virus-associated nephropathy affects 1–10% of kidney Tx 
recipients and is primarily due to BK virus reactivation and replication in urothelial cells 
(Kumar 2010). Diagnosis of polyomaviruses can be confirmed by polymerase chain 
reaction (PCR) from plasma or urine, and with SV40 staining of a core needle biopsy 
sample. No effective antiviral medication for polyomaviruses exists and judicious 
reduction of immunosuppression with rejection surveillance is advised (Fishman 2007, 
Green, Michaels 2007, Egli et al. 2009). 
 
Currently at our center, RTx patients receive two types of prophylactic therapy. 
Valganciclovir is used for six months in case of recipient or donor cytomegalovirus-
seropositivity. Co-trimoxazole is administered for twelve months post-RTx to prevent 
pneumocystis jirovecii pneumonia. 
2.2.3 Malignancies 
Immunosuppression-induced malignancies are more commonly diagnosed in parallel with 
improved graft and patient survival rates. However, the pattern of malignancies in 
pediatric Tx patients differs from that of general childhood population and adult organ 
recipients. The reported probability of developing de novo malignancy was estimated by 
Coutinho et al. (2001) at 17% 25 years after the ﬁrst pediatric RTx, a 10-fold incidence 
rate compared to the general age-matched population. In another study, over a 10-year 
period the risk of malignant lymphoma in Tx patients was 12-fold higher than in a 
matched nontransplant population (Opelz, Dohler 2004).  
 
PTLD comprises a family of conditions occurring in organ Tx patients having evidence of 
EBV and lymphoid growths, thus, straddling the borderline of infection and neoplasia 
(Nalesnik, Starzl 1994). The majority (85–90%) of PTLD cases in children are EBV-
driven, arising almost without exception in the first 3 post-RTx years (Webber, Green 
2007). Furthermore, PTLD is more frequent in patients who are seronegative for EBV at 
the time of RTx and subsequently develop primary EBV infection (Ho et al. 1988). Adults 
are usually EBV-seropositive, explaining the difference reported by Penn et al. (1998) that 
in pediatric Tx patients PTLD accounts for 52% of all the malignancies compared to 15% 
in adult Tx patients. Furthermore, along with the improved patient and graft survival and 
advanced immunosuppression, the PTLD incidence has increased during the recent years 
(Dharnidharka et al. 2002). 
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2.3 Long-term outcome 
2.3.1 Growth 
Notable growth retardation, a significant concern for the patients and their families, is 
common in children with ESRD and is of multifactorial origin (Schaefer 2004). According 
to the most recent NAPRTCS data (2001), children with worse height deficit at the start of 
dialysis improve slightly, but those with less deficit at baseline experience worse deficit 
after 2 years of dialysis. Uremia causes nausea, vomiting, and lack of appetite. Metabolic 
acidosis inherent in uremia also disturbs the somatotrophic hormone axis and at the same 
time, results in excessive catabolic protein wasting state that could contribute to growth 
retardation (Schaefer 2004, Boirie et al. 2000). Moreover, in CNF, the most common 
underlying disease preceding RTx in Finland, severe loss of protein leads not only to 
malnutrition but also to endocrine alterations possibly distorting growth (Holmberg et al. 
2004). Growth in children with ESRD is thus characterized by a continuous gradual 
deviation from the normal growth, a detrimental status that can be decelerated before RTx 
by nutritional management, growth hormone (GH) therapy, and dialysis (Kari et al. 2000, 
Johansson et al. 1990, Laakkonen et al. 2010). 
 
RTx corrects the effect of preceding uremia and provides better conditions for growth, 
which is seen as accelerated growth after transplantation (Ingelfinger et al. 1981). Even 
though the growth velocities after RTx are greater than those of similarly aged children in 
dialysis, the restoration of kidney function does not fully restore the growth potential, and 
adult height is commonly blunted in pediatric RTx patients (Turenne et al. 1997, 
Aschendorff et al. 1990, Harambat et al. 2014). Children having received a kidney graft 
from a living related donor show better growth post-Tx than those having received a 
deceased donor graft (Pape et al. 2005). During the past quarter century, the mean height 
standard deviation (SD) score (hSDS) deficit at the time of RTx has improved over the 
years from -2.43 SD in 1987 to -1.23 in 2009, with an overall average of -1.75 SD 
(NAPRTCS 2010). The major factors affecting growth, in addition to age and height at the 
time of RTx, are kidney graft function and medication post-RTx. 
 
Catch-up growth is reportedly more apparent in patients transplanted in early childhood in 
comparison with those aged older than five years at RTx (Figure 2) (NAPRTCS 2010). 
Regardless of the age at RTx, however, the growth plateaus after the initial 2 years 
following transplantation. Also, an inverse correlation between the height at RTx and the 
rate of catch-up growth has been reported, thus the more stunted the patient is at RTx, the 
greater catch-up growth is observed (Bosque et al. 1983, Tejani, Cortes & Sullivan 1996, 
Qvist et al. 2002a). In this respect, age at RTx and duration of uremia may also distort the 
pubertal growth spurt (see below). 
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Figure 2. Mean height scores and growth patterns by age at transplant. Younger recipients 
experience better improvement in mean growth deficit after transplantation than the older ones. (Adapted 
from NAPRTCS 2010). 
 
 
Growth is sensitive to deteriorated renal function in a similar manner in chronic failure of 
native kidneys or renal graft. A significant negative correlation between serum creatinine 
and decrease in height Z score was already reported by Tejani et al. in 1993. Soon 
afterwards, the growth-suppressive effect of poor renal function was confirmed to be 
independent of corticosteroid dosage (Hokken-Koelega et al. 1994b, Jabs et al. 1996). 
 
The role of glucocorticoids affecting growth is obvious (Schaefer 2007). Results from 
studies analyzing the effect of steroid therapy modification, withdrawal, or primary 
avoidance have shown that catch-up growth can be promoted by adjusting glucocorticoid 
treatment. Broyer et al. (1992) reported that the mean change in hSDS was better in 
patients with alternate-day dosing than in those with daily regimen even though the 
cumulative dose was the same between the groups. Similarly, Höcker et al. reported in 
2004 that patients with discontinuation of steroids in the second post-RTx year had height 
increased from -1.60 SD to -1.0 SD at 4 years post-RTx in comparison with unchanged 
hSDS in those with continued daily steroids, while Sarwal et al. (2012) reported that 
recipients under 5 years of age showed improved linear growth with steroid-free compared 
with steroid-based regimen. In the latter study, the results anticipated that, especially 
among older children receiving kidney grafts, there are other factors than steroids 
affecting catch-up growth. One explanation was presented by Kapila et al. (2001) 
reporting that reduced bioactivity of insulin-like growth factor-1, an important growth 
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promoter produced by stimulation of GH, occurs in RTx patients independent of steroid 
treatment. 
 
GH therapy is effective in children with chronic renal failure and after RTx (Fine et al. 
1996, Maxwell, Rees 1998). It can be initiated already during the first year of life in order 
to preventing growth retardation (Mencarelli et al. 2009). Despite an adequate GH 
therapy, the final height (FH) in RTx recipients remains blunted (Rodriguez-Soriano et al. 
2000). GH therapy has also raised controversial questions on safety issues (Benfield, 
Kohaut 1997, Friedman 1997). The worries have been related to findings that GH 
augments immune function in several ways, such as promoting antibody synthesis, 
activating cytotoxic T- and natural killer cells, and increasing the production of tumor 
necrosis factor alpha (Kelley 1990). The possible immunoactivation-promoted worse graft 
survival or increased rejection rates raised concerns at first, but opinions have since been 
for and against such effects (Chavers et al. 1995, Laine et al. 1996, Fine et al. 2002). The 
present general opinion suggests that GH therapy does not threaten the allograft function, 
but patients with a history of at least one AR may have increased risk of AR during GH 
therapy (Broyer 1996, Guest et al. 1998, Fine, Stablein 2005). 
2.3.2 Pubertal development 
Puberty is a complex developmental process occurring in late childhood. It consists of 
rapid physiological alterations, such as maturation of secondary sexual characteristics, 
attainment of adult height, and changes in body composition (Diamanti-Kandarakis, Gore 
2012). Pubertal development is thus the transitional phase from sexual immaturation to 
gained reproductive capacity. Puberty is initiated by the awakening of the dormant 
hypothalamic-pituitary-gonadal axis, the primary mechanism of which, however, remains 
unclear (Parent et al. 2003). The gonadotropin release hormone (GnRH) pulse generator in 
the hypothalamus activates secretion of luteinizing hormone (LH) and follicle-stimulating 
hormone (FSH) from the pituitary gland, resulting in secretion of testosterone from the 
testes and estrogen from the ovaries in boys and girls, respectively (Figure 3). The onset 
and progress of puberty is assessed by the 5-stage scale of external primary and secondary 
sexual characteristics, the appearance of breasts in girls and genitalia in boys, and pubic 
hair in both genders, as reported by Marshall and Tanner (1969 and 1970). The first sign 
of puberty is an increase in testes volume in boys and an advance in breast development in 
girls, but the average schedule varies individually as presented in Figure 4. 
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Figure 3. Gonadotropin-releasing hormone (GnRH) is secreted from the hypothalamus and 
stimulates secretion of gonadotropins follicle-stimulating hormone (FSH) and luteinizing hormone (LH) 
from the pituitary gland. LH and FSH in turn stimulate the sex steroid (testosterone, estrogen, and 
progesterone) secretion from the gonads. As a result of the negative feedback loop, the sex steroids inhibit 
the secretion of GnRH and the gonadotropins. 
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Figure 4. Diagram of the sequence of events at puberty in girls and boys. An average girl and boy are 
represented in relation to the scale of ages and the range within which some of the changes occur is 
indicated below. (Adapted from Marshall and Tanner 1970). G. rating refers to stages for genitalia. 
 
 
Data on pubertal onset and tempo in pediatric RTx patients are scarce in comparison with 
studies of somatic growth. The available data, however, suggest that delayed puberty is 
common. In the two studies from the 1980s, Rees et al. (1988) found delay in the 
appearance of secondary sexual characteristics in both genders, and Van Diemen-
Steenvoorde and Donckerwoncke (1988) reported similarly of delayed puberty. In 2004, 
Nissel and co-workers reported that onset of puberty is markedly delayed in RTx patients 
transplanted prepubertally. In the most recent study on pubertal onset, delayed sexual 
maturation was found in 22% of girls and 19% of boys (Ghanem et al. 2010). In keeping 
with the general pubertal delay, female pediatric RTx recipients experience delayed 
menarche. Van Diemen-Steenvoorde et al. reported in 1987 that menarche occurred in 
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girls transplanted prepubertally at the mean age of 15.3 years, but the concomitant mean 
bone age was 12.9 years, the typical age at which menarche occurs. 
 
Pubertal growth is driven by sex steroids (Karlberg 1989). The loss of FH in pediatric RTx 
patients, however, is mainly determined by infancy and childhood growth, which are 
dependent on nutrition and GH (Schaefer 2004). ESRD and RTx may have a deleterious 
effect on the pubertal growth spurt, the apparent peak in growth velocity during 
adolescence. Turenne and co-workers (1997) reported of absent substantial pubertal 
growth spurt in a large study of more than 700 pediatric RTx patients. Two other studies 
have also reported a lack of pubertal growth spurt, emphasizing its contribution to the low 
adult height in concert with the preexisting height deficit at the time of RTx (Nissel et al. 
2004, van Diemen-Steenvoorde et al. 1987). As mentioned above, GH therapy has indeed 
paved the way for height gain after RTx. It significantly improves growth and corrects the 
existing height deficit without interfering with growth and bone health. Haffner et al. 
(2000) reported that GH therapy was associated with accelerated prepubertal bone 
maturation, but not with shortening of the pubertal growth spurt, however. In contrast, 
three studies reported that GH therapy does not accelerate skeletal maturation or advance 
pubertal development (Hokken-Koelega et al. 1996, Van Dop et al. 1992, Hokken-
Koelega et al. 1994a). 
2.3.3 Fertility 
ESRD disturbs the normal sexual function by various mechanisms, such as uremic milieu, 
neuropathy, vascular disease, pharmacological therapy, and psychological stress. The 
deterioration of the hypothalamic-pituitary-gonadal axis leads to impaired fertility in both 
genders. RTx is reportedly the most effective means to recover the hormonal function and 
restore the reproductive capacity (Palmer 1999, Lim, Fang 1975, Holdsworth, de Kretser 
& Atkins 1978, Prem et al. 1996). Kim et al. (1998) reported of resolved menstrual cycle 
dysfunction subsequent to RTx. Quite recently, Akbari et al. (2003) reported of almost 
normal steroidogenic function and recovery of spermatogenic function. However, 
conflicting results with continuation of hormonal, seminal, and ovarian disturbances after 
RTx have also been reported (Bozzini et al. 2013, Tauchmanova et al. 2004). The data are 
still scarce, especially in detailed long-term follow-up after pediatric RTx during 
childhood or adolescence. In male recipients, Inci et al. reported in 2006 that 
spermatogenesis does not improve after pediatric RTx and Koyun et al. (2009) showed 
that earlier onset and longer duration of RRT emphasize the impairment of reproductive 
function. 
 
The gonadotoxic effect of some immunosuppressive medication, especially 
cyclophosphamide and sirolimus, is known (Boobes et al. 2010, Watson, Rance & Bain 
1985, Bogdanovic, Banicevic & Cvoric 1990, Tondolo et al. 2005, Skrzypek, Krause 
2007, Zuber et al. 2008). Germinal cell aplasia has been documented in 
cyclophosphamide-treated patients with intact Leydig cell appearance in testicular biopsy 
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(Etteldorf et al. 1976). Sirolimus interferes with the stem cell factor/c-Kit system, thus 
blocking spermatogenesis (Feng, Ravindranath & Dym 2000). Furthermore, deterioration 
of rat germ cell function by the CNIs has also been reported (Masuda et al. 2003, 
Hisatomi et al. 1996, Chen et al. 2013), but the results from studies in humans have been 
contradictory (Handelsman et al. 1984, Haberman et al. 1991, Samojlik et al. 1992). 
2.3.4 Cardiovascular and metabolic outcome 
CVD, accounting for 40% of late mortality in adult RTx recipients with functioning graft, 
is the most important long-term risk factor limiting the success of RTx (Ojo et al. 2000). 
The short-term complications and their incidences, risk factors, and treatment options are 
better known, in contrast to the long-term problems of which data have been recently 
started to emerge. 
 
The same traditional risk factors for CVD (such as age, cigarette smoking, obesity, 
hypertension, dyslipidemia, diabetes) as in the general population are also predictive 
among RTx recipients (Kasiske 2001). In addition, the RTx patients have non-traditional 
risk factors (such as recurrent rejections and ESRD combined with diabetes) that show 
independent contribution to ischemic heart disease (Kasiske, Chakkera & Roel 2000). 
Native kidney nephrectomy has been indicated by severe hypertension before RTx but the 
results on long-term cardiovascular outcome are reportedly modest (Cavallini et al. 2010). 
Even though the death rate from CVD is considerably lower for adult RTx recipients than 
for dialysis patients, it still is double the rate in general population (Foley, Parfrey & 
Sarnak 1998). RTx children and adolescents have also severely impaired cardiorespiratory 
fitness in comparison with their healthy peers (Tangeraas 2010). The etiology of CVD as 
well as its risk factors is multifactorial. For example, immunosuppressive agents directly 
contribute to the risk for CVD but also predispose the patients to other risk factors, such as 
hypertension, dyslipidemia, and diabetes mellitus. 
 
Hypertension is a common and serious complication in RTx recipients (Baluarte et al. 
1994, Sorof et al. 1999). It associates with impaired graft survival and increased CVD 
morbidity and mortality (Tutone et al. 2005, Mange et al. 2000, Mitsnefes, Khoury & 
McEnery 2003). BP monitoring is therefore crucial in the follow-up of RTx patients. The 
reported prevalence of hypertension after RTx varies, however, mainly because of the 
different methods of measurement and definitions of hypertension used in various studies. 
 
Ambulatory BP monitoring (ABPM) provides data on daytime, nighttime, and 24-hour BP 
levels and it has been shown to be superior to single office BP measurements, especially 
since it can reveal white-coat and nocturnal hypertension (Calzolari et al. 1998, Ferraris et 
al. 2007). Another advantage of the method is the ability to analyze the physiological 
decrease of BP during the night (nocturnal dipping). In a study by Lipkin et al. (1993), 
nocturnal dipping was found to associate with greater left ventricular mass in adult 
patients. In a pediatric study by Seeman et al. (2006), no such relation could be confirmed, 
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however. The main findings of several pediatric studies using 24-hour ambulatory BP 
monitoring (ABPM) on hypertension are summarized in Table 4. Several studies have 
indeed reported of predominance of nocturnal hypertension in RTx recipients (Seeman et 
al. 2006, Giordano et al. 2000, Morgan et al. 2001, McGlothan et al. 2006). Furthermore, 
ABPM has been reported to have better correlation with left ventricular hypertension and 
renal function than office BP measurements (Mitsnefes et al. 2001, Jacobi et al. 2000). 
 
 
Table 4. Studies reporting ambulatory hypertension in pediatric renal transplantation patients. 
Study 
Number of 
patients 
Definition of hypertension 
Prevalence of 
hypertension 
Lingens et al. 1997 27 BP >95th percentile or medication 70% 
Giordano et al. 2000 37 BP >95th percentile 62% 
Sorof et al. 2000 42 BP load >25% (BP >95th percentile) 83% 
Morgan et al. 2001 45 BP >95th percentile and BP load >30% 62% 
Serdaroglu et al. 2005 26 BP >95th percentile and BP load >30% 73% 
Seeman et al. 2006 36 BP >95th percentile or medication 89% 
Gülhan et al. 2014 29 BP >95th percentile 76% 
BP, blood pressure. 
 
 
The abovementioned studies emphasize the importance of the use of ABPM in the follow-
up of Tx patients but the method still has significant limitations. ABPM provides 
excessive data on 24-hour BP, but reference values for indexing the results with regard to 
healthy children and adolescents are limited to Caucasian subjects (Wühl et al. 2002). 
Furthermore, for several years the relative importance of the parameters provided by 
ABPM (BP index, load, and dipping) was unclear until the American Heart Association 
(AHA) provided guidelines for interpretation of ABPM in 2008 (Urbina et al.). This 
classification uses a combination of systolic and diastolic office and mean ambulatory BP 
values, and BP loads in the staging of ABPM. 
 
CNIs can contribute to hypertension by several mechanisms, the sum effect being 
vasoconstriction. The most important factors are renal or peripheral vasoconstriction, 
increased sympathetic and renin-angiotensin system activity, impaired nitric oxide-
induced vasodilatation, sodium and water retention, and excess release of several 
vasoconstrictors (endothelin, thromboxane, and prostaglandins) (Buscher et al. 2004, 
Curtis 1994). Glucocorticoids, in turn, have the potential to alter both circulating volume 
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and vascular resistance (Brem 2001). The newer immunosuppressives, such as 
mycophenolate mofetil and sirolimus, seem not to predispose patients to hypertension 
(Buscher et al. 2004). 
 
Overweight and obesity are a major concern in the long-term follow-up of RTx patients 
(Smith, McDonald 2007). Most children gain weight rapidly in the early post-Tx period 
with an average increase of 0.81 SD during the first year after the operation (NAPRTCS 
2010). In a large pediatric study by Hanevold et al. in 2005, obese children aged 6 to 12 
years had a higher risk for death than those of normal weight, and death was more likely 
as a result of cardiopulmonary disease. Other studies have also reported an association 
between body mass index (BMI) and worse survival rate after RTx (Aalten et al. 2006, 
Meier-Kriesche, Arndorfer and Kaplan 2002, Hoogeveen et al. 2011). 
 
Dyslipidemia occurs in more than half of the pediatric RTx recipients in Europe 
(Bonthuis et al. 2014) and similar results have been reported by studies in the US (Wilson 
et al. 2010, Saland et al. 2010). In concert with a link to obesity and immunosuppressive 
medication, dyslipidemia may serve to aggravate renal injury (Weinberg 2006).  
 
Glucose metabolism alters notably during postoperative follow-up. Hyperglycemia is 
common during the initial and early maintenance therapy due to postoperative stress and 
higher doses of immunosuppressive medication, especially glucocorticoid and CNI. Even 
though the diabetogenicity of immunosuppressants is reportedly dose-dependent, 
hyperglycemia in the early postoperative phase is associated with later incidence of 
diabetes (Kuypers et al. 2008). The predominant cause for corticosteroid-induced diabetes 
post-RTx seems to be insulin resistance, but also stimulation of gluconeogenesis and 
impaired insulin secretion have been reported to promote diabetes (Penfornis, Kury-Paulin 
2006, Hjelmesaeth et al. 2005). CNIs induce diabetes post-RTx by a number of 
mechanisms, including insulin resistance, pancreatic beta cell toxicity, and decreased 
insulin secretion (Penfornis, Kury-Paulin 2006). The deleterious effects, which are more 
prominent with tacrolimus than with CsA, are in part dose-dependent and, diabetes may 
thus reverse after dose reduction (Heisel et al. 2004, Prokai et al. 2008, Rodrigo et al. 
2005, Zielinska et al. 2003). 
 
Metabolic syndrome (MS) is a constellation of CVD-promoting interrelated metabolic 
risk factors including obesity, hypertension, dyslipidemia, and impaired glucose 
metabolism (Hanevold et al. 2005, Zimmet et al. 2007). The current diagnostic criteria of 
the American Heart Association are based on the preceding Adult Treatment Panel III 
(ATP III) criteria and MS is diagnosed in the presence of abnormal results in a minimum 
of three out of five risk factors (overweight, hypertension, reduced high-density 
lipoprotein (HDL), elevated triglycerides, and elevated fasting glucose) (Grundy et al. 
2005, National Cholesterol Education Program (NCEP) Expert Panel on Detection, 
Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel 
III) 2002). The MS has been reported to associate with decreased renal allograft function, 
but the risk factors of MS may not contribute equally to long-term allograft function (de 
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Vries et al. 2004). In that study de Vries et al. found that only systolic BP and 
hypertriglyceridemia were independently associated with impaired renal function. 
2.3.5 Psychological and cognitive outcome 
Many of the children undergoing RTx have suffered from chronic illness affecting their 
cognitive development (Cadman et al. 1987). Failure of a major organ such as kidney 
often leads to neuropsychological sequels with cognitive defects (Farmer 1994). 
Additional disabilities may increase the risk, especially in the case of early onset of the 
underlying disease, long-term end-stage organ failure and treatments, which can affect the 
developing brain. Although RTx restores the kidney function and removes the toxic 
effects of uremia, some of the perturbations and complications may be irreversible. 
 
In school-aged RTx children, intellectual functioning is normal in the majority of patients 
(Falger et al. 2008). According to a study using siblings as matched controls, the results 
showed significantly worse intelligence scores for RTx recipients (Brouhard et al. 2000). 
According to a Finnish study, the majority (79%) of children having received a RTx 
before the age of 5 years attend normal school and 76% have normal motor performance 
(Qvist et al. 2002b). More recently, however, the same group reported of lower intelligent 
quotient in RTx patients with respect to test norms (Haavisto et al. 2012). In addition, they 
found that on neuropsychological assessment the RTx recipients scored worse than the 
control group in verbal and visuospatial domains. 
 
Successful pediatric RTx permits the child to develop and live quite normally. This could 
mean the capability to attend school in parallel with their healthy peers. Still, re-entry to 
school and normal life can be limited in several ways. The changed body image in respect 
to that before a chronic illness and routine hospital visits, for instance, can be a significant 
burden for youngsters. Thus, health-related quality of life (HRQOL) issues have become 
more important. HRQOL can be evaluated, especially considering small children, from the 
perspective of a close proxy such as a parent. As a child grows older, more focus should 
be given to the patient’s own impression of HRQOL by assessing HRQOL from the 
recipient’s perspective. Parents can, however, underestimate distress and depression in 
children who had a Tx (Shemesh et al. 2005). 
 
In a study by Sundaram et al. (2007), adolescent RTx recipients saw their quality of life as 
similar to healthy school-aged population. Recently, Haavisto et al. (2013) conducted a 
study on renal, heart (HTx), and liver (LTx) Tx recipients, and the results showed poorer 
HRQOL in preadolescents (8- to 11-year-old) compared with age-matched healthy peers. 
Lower HRQOL was associated with shorter follow-up after Tx, congenital disease, and 
psychiatric/neurological comorbidity (Haavisto et al. 2013). Similarly, Diseth et al. (2011) 
reported of higher levels of mental health problems and lower HRQOL in RTx children 
compared to both healthy children and those with a history of acute lymphoblastic 
leukemia. In line with the improved survival rates after pediatric RTx and the constantly 
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increasing number of adolescents surviving into adulthood, the issue of their quality of life 
is of paramount importance. 
2.3.6 Survival 
The graft survival rates in Finland are acceptable, with the 7-year survivals even for 
children transplanted under 5 years of age exceeding 80% (Qvist et al. 1999). Overall, 
living donor pediatric kidney recipients have better unadjusted 1-, 3- and 5-year graft 
survival than deceased donor recipients (Magee et al. 2008). According to Akkina et al. 
(2008), graft survival after a preemptive RTx is not necessarily positively correlated with 
the pretransplant estimated GFR. During the last two decades, the half-life of first kidney 
grafts has not improved (Meier-Kriesche, Schold & Kaplan 2004) and, accordingly, the 
attrition rate after the first year post-RTx has remained stable despite the better rejection 
prophylaxis (Lamb, Lodhi & Meier-Kriesche 2011). A single episode of cellular rejection 
with no components of vascular rejection and good response to rejection therapy allowed a 
similar graft survival as in those without rejection (McDonald et al. 2007). Chronic and 
acute rejections are, however, the most common reasons for graft failure in the US data 
(NAPRTCS 2010).  
 
Graft thrombosis remains one of the major risk factors for graft failure, especially in 
children under two years of age, accounting for 12% of index graft loss (Singh, Stablein & 
Tejani 1997). Accordingly, patients with congenital nephrotic syndrome have graft failure 
due to thrombosis more frequently than patients with other primary diseases (8.3% vs. 
2.9%, p = 0.002) (Kim, Stablein & Harmon 1998). Death with functioning graft, 
recurrence of original kidney disease, and discontinued medication are also reasons for 
graft loss worth noticing (NAPRTCS 2010). 
 
The patient survival rate in Finland is world-class, with the 7-year survivals even for 
children transplanted under 5 years of age at 98% (Qvist et al. 1999). The patient survival 
rates, especially during the first post-Tx year, have improved over time and currently the 
10-year patient survival rate in the US has exceeded 90% (Van Arendonk et al. 2014). 
Furthermore, the short-term outcomes of adult kidney grafts in small children are 
comparable to those of size-matched grafts (Goldsmith et al. 2010). CVD has kept its 
position as the most common cause of death with a functioning graft followed by infection 
and malignancy, but the overall death rates have been decreasing for the time being (Ojo 
et al. 2000, Pilmore et al. 2010, NAPRTCS 2010). 
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3 Aims of the study 
The goal of this thesis was to examine the long-term endocrinologic and metabolic 
development and outcome during childhood, adolescence, and young adulthood. By the 
earliest possible identification of the patients at greatest risk for endocrinologic and 
metabolic problems their long-term prognosis and outcome can further be improved by 
means of enhanced therapy and follow-up. 
 
The aims of the current study were: 
 
1. To examine pubertal development and factors associating with it, with emphasis on 
reproductive hormone levels and growth. 
 
2. To assess the reproductive hormone levels, testicular volumes, and semen quality in 
young men after RTx and to investigate the prevalence of testicular insufficiency and 
subsequent risk for infertility. 
 
3. To study lipid and glucose metabolism, and MS in pediatric RTx recipients and to 
evaluate their possible impact on long-term graft function. 
 
4. To analyze the ABPM profiles of children and adolescents with a renal, heart, or 
liver transplants and to study in RTx recipients the correlation between the ABPM 
variables and metabolic factors and concurrent and long-term graft function. 
 
 
 
 
 
35 
4 Subjects and methods 
4.1 Patients and controls 
This thesis comprises all 218 patients having undergone RTx during childhood or 
adolescence by March 2011 in Finland. Since 1986 all pediatric RTx operations in Finland 
have been performed at the study center (Children’s Hospital, Helsinki University Central 
Hospital). All the recipients visited for postoperative follow-up at 3, 6, 12, 18, and 24 
months post-RTx and annually thereafter until the age of 18–20, after which they are 
transferred to adult care. All studies included a retrospective part, in which hospital charts 
were reviewed (Table 5). 
 
Study I. The overall study cohort consisted of 109 RTx recipients. In the first part of the 
study we analyzed retrospectively clinical data on puberty in 98 RTx recipients. In the 
second cross-sectional part, data on reproductive hormones related to puberty were 
assessed in 87 patients, consisting of 50 consecutive patients who had their annual visit 
between February 2009 and January 2010 and of an additional 37 RTx patients who were 
older than 15 years at the time of sampling. 
 
Study II. Fertility was studied in 24 male RTx recipients. The patient selection is 
presented in detail in Figure 5. The 56 controls were recruited from occupational health 
services in the Helsinki municipality area and Helsinki University Central Hospital. None 
of the subjects were on testosterone supplementation at the time of the study.  
 
Study III. The data on metabolic characteristics in 210 RTx patients were collected at 1.5, 
5, 9, and 13 years post-RTx. Seventeen patients had lost the first graft and 10 of them 
were included as new study patients. The remaining seven patients were included only 
once (after retransplantation). Eleven patients had undergone a combined liver and kidney 
transplantation. 
 
Study IV. A total of 111 RTx recipients with ABPM data were analyzed. In case of 
missing data at 5 years post-Tx we used the nearest subsequent monitoring up to 10 years 
post-Tx. Four subjects had undergone a combined kidney and liver Tx and their data were 
analyzed in the RTx subgroup. 
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Table 5. Features of the study population. 
Study I II III IV 
Study issue Puberty Male fertility Metabolic Blood pressure 
Number of 
patients 
 
109 24 210 111 
Inclusion criteria Follow-up >1 y 
Age >8 y 
Age at RTx <16 y 
 
Follow-up >5 y 
Age >18 y 
Age at RTx <18 y 
Follow-up >1.5 y Follow-up >5 y 
 
No re-RTx 
Exclusion criteria Lack of sufficient 
data on puberty and 
growth 
Associated co-
morbidity 
 
 
RTx within 1 y 
No Lack of ABPM 
data 
 
 
Acute rejection 
within 3 months 
 
 
Control group No Healthy men without 
history of 
immunosuppression 
No Other solid organ 
Tx recipients 
 
 
Number of 
controls 
- 56 - 29 HTx patients 
13 LTx patients 
 
Y, year; RTx, renal transplant, HTx, heart transplant, LTx, liver transplant. 
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Figure 5. Flow chart of patient selection in Study II. Sixteen men could not be contacted with 
repeated invitation letters and phone calls. 
4.2 Methods 
4.2.1 Clinical data collection 
A retrospective analysis of patient data on the underlying disease before RTx, initiation 
and length of dialysis, age at RTx, kidney graft function, growth, and immunosuppressive 
medication was performed in all the Studies I-IV. In addition, data on other medication 
(antihypertensive, GH), bone age, and pubertal development were collected, as 
appropriate, concerning the study protocols. In Study II, a questionnaire concerning 
marital status, wish for having children, possible infertility treatments, and number of 
children fathered was filled out by the subjects. Patients and controls were assessed 
similarly. 
 
Growth was assessed by measuring height and weight, and determining hSDS and height-
adjusted weight ratio in percentages of the median using the Finnish growth curves for 
children (Sorva et al. 1990, Pere 2000). BMI was calculated by dividing weight by height 
squared (kg/m2). Bone age was determined from a plain radiograph of the left hand 
according to Greulich and Pyle (1959). Cut-off for short stature was defined as hSDS 
below -1.5 in Study I and -2.0 in Study III. Overweight was defined as weight-for-height 
exceeding 20% of the gender- and height-adjusted median (relative weight >120%), 
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except for Study IV in which overweight was defined, in line with the International 
Obesity Task Force Criteria recommendations, as BMI exceeding the percentile passing 
through BMI 25 kg/m2 at the age of 18 years, according to the new Finnish growth 
references (Cole et al. 2000, Saari et al. 2011). Concerning pubertal growth, peak height 
velocity (PHV) was defined in line with Aksglaede et al. (2008) as the age at maximal 
height velocity after the age of 8.0 and 10.0 years for girls and boys, respectively. The age 
at minimum height velocity rate before PHV was defined as the onset of growth spurt 
(OGS). For FH (adult height) we recorded the height when growth velocity was less than 
0.5 cm/year and Tanner stage 5 was reached. Data on RTx recipients transplanted after the 
onset of puberty were excluded when analyzing pubertal growth and factors affecting the 
pubertal onset in Study I. 
 
Pubertal maturation was clinically evaluated according to Tanner (1962). Achievement 
of Tanner stage 2 was defined as the onset of puberty and the length of puberty as time 
between Tanner stage 2 and first evaluation of completed puberty (stage 5). In case of 
delayed onset of puberty or menarche, the age of the patient at the hallmark was more than 
2 SD above the average in the Finnish population (Ojajärvi 1982). Testes were measured 
with a ruler and testicular volume was calculated using the common formula for prolate 
spheroid: Volume (mL) = 0.52 x longitudinal diameter (cm) x transversal diameter 
squared (cm2) (Hansen, With 1952). The mean volume of both testes was used for data 
analyses except in case of scrotal hydrocele or preceding unilateral orchiectomy, when the 
volume of the intact testicle was used. 
4.2.2 Blood pressure measurements 
Office BP was measured at an outpatient visit or at the beginning of annual follow-up 
visit. In Study IV, office BP data were from the visit during which the ABPM was 
performed, or a preceding outpatient visit not more than 3 months previously. Office BP 
measurement was done three times using an automated oscillometric device and a size-
appropriate cuff after the patient had remained seated for five minutes and the average BP 
was used in the analyses. 
 
The 24-hour ABPM was performed with one of the three automated devices used at the 
study center one at a time over consecutive time periods: ABPM 5100 or ABPM 6100 
(Welch 122 Allyn Inc., Skaneateles Falls, NY, USA) or Schiller BR-102 (Schiller AG, 
Baar, Switzerland), which ensures the accuracy of auscultator results by using 
oscillometric measurements as backup. The devices have been tested to meet the 
Association for the Advancement of Medical Instrumentation US National Standard or the 
British Hypertension Society Standard (Denchev, Simova & Matveev 2007, Modesti et al. 
1996). The ABPM was disqualified if a longer than 2-hour continuous interruption 
existed, or if the device- or user-approved measurement count was less than 70% of the 
total. The ABPM device was programmed to measure BP every 30 minutes between 7 am 
and 10 pm and hourly thereafter until 7 am the following morning. The patients kept a 
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diary based on which daytime and nighttime periods were defined. In case the information 
was not provided by the patient, daytime was defined as the period from 8 am to 8 pm and 
nighttime as 12 am to 6 am in order to rule out bias by individual bedtime habits as 
suggested by Jones and Sinha (2011). 
 
Office BP values were indexed by dividing the systolic and diastolic BP values by the 
gender- and height-adjusted cut-off values according to the criteria of the fourth report on 
the diagnosis, evaluation, and treatment of high BP in children and adolescents (National 
High Blood Pressure Education Program (NHBPEP) Working Group on High Blood 
Pressure in Children and Adolescents 2004). Similarly, daytime and nighttime ambulatory 
BP indices were calculated by using the cut-off values for healthy European Caucasian 
children provided by Wühl et al. (2002). BP load was calculated by dividing the count of 
measurements exceeding those 95th percentile cut-off values by the count of measurements 
during the study period. Nocturnal dipping was denoted as the difference between average 
daytime and nighttime BPs. 
 
Hypertension was defined in Study III as the use of antihypertensive medication or office 
BP levels above the 95th percentile cut-off by the abovementioned NHBPEP fourth report. 
In Study IV, the ABPMs were classified according to the recent update on the 2008 AHA 
recommendation (Flynn et al. 2014). Office BP was normal in case of being under the 90th 
percentile and hypertensive if over 95th percentile according to the normative data 
provided by the NHBPEP. Being equal to or above the 90th percentile or 120/80 mmHg 
but below the 95th percentile cut-off value, the office BP was considered prehypertensive. 
Regardless of antihypertensive medication, mean ambulatory BP was defined 
hypertensive if at least one of the daytime or nighttime, systolic or diastolic BP index was 
1.0 or more. Similarly, if any of the BP loads was 25–50% it was regarded hypertensive or 
severely hypertensive in case of being over 50%. Thus, patients with two related patterns 
on ABPM remained unclassified: 1. Hypertensive office BP, normal BP indices, but 
elevated BP loads; and 2. Normotensive office BP, normal BP indices, but elevated BP 
loads. 
4.2.3 Biochemistry 
Reproductive hormone levels (testosterone, estradiol, FSH, LH, prolactin, and sex 
hormone-binding globulin (SHBG)) were assessed using standardized methods in Studies 
I and II. Inhibin B (Diagnostic Systems Laboratories, Inc., Webster, TX, USA) and anti-
Müllerian hormone (Immunotech, Beckman Coulter Ltd., UK) were measured using a 
commercially available enzyme-linked immunosorbent assay. Assessment of hormone 
levels was made in respect to normal values reported by three Danish studies (Hagen et al. 
2010, Andersson et al. 1997, Aksglaede et al. 2009). Androgen deficiency was defined by 
serum testosterone level <10 nmol/L in Study II (Bhasin et al. 2010). 
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Semen samples were analyzed within an hour after ejaculation according to World Health 
Organization guidelines (2010). Sperm DNA fragmentation index (DFI) was assessed by 
sperm dispersion test by counting the proportion of sperm cells with fragmented DNA 
(Fernandez et al. 2003). A DFI over 30% was considered abnormal, based on a previous 
report of lower pregnancy rate with results exceeding that cut-off (Evenson, Wixon 2008). 
 
Glucose and lipid metabolism were assessed from blood samples drawn after an 
overnight fasting. Analyses were performed using standardized methods for blood 
glucose, insulin, glycosylated hemoglobin (GHbA1c), total cholesterol, HDL and low-
density lipoprotein (LDL), triglyceride and uric acid. In Study III, 2-hour oral glucose 
tolerance test (OGTT; glucose load 1.75 g/kg up to 75 g) with the measurement of glucose 
and insulin levels at 0, 60 and 120 minutes postload was performed at 5 years post-RTx. 
According to the OGTT results, patients were classified as having normal glucose 
tolerance (fasting blood glucose <5.6 mmol/L and 2-hour glucose value <6.7 mmol/L), 
impaired fasting glucose (IFG; fasting blood glucose 5.6–6.0 mmol/L and 2-hour glucose 
value <6.7 mmol/L), impaired glucose tolerance (IGT; fasting blood glucose <6.1 mmol/L 
and 2-hour glucose value 6.7–9.9 mmol/L), or type 2 diabetes (fasting blood glucose ≥6.1 
mmol/L or 2-hour glucose value ≥10.0 mmol/L). MS was diagnosed if a minimum of three 
of the five risk factors (overweight, hypertension, reduced HDL, elevated triglycerides, or 
elevated fasting glucose) were abnormal, in line with the diagnostic criteria of the 
American Heart Association (Grundy et al. 2005). 
 
Kidney function in terms of GFR (mL/min/1.73 m2) was measured at every follow-up 
visit by 51Cr-EDTA clearance, except in Study II, in which GFR was estimated using the 
patient’s most recent creatinine value and the calculation formula developed by the 
Modification of Diet in Renal Disease Study Group (Levey et al. 1999). GFR values were 
corrected with a one-pool approximation model according to modified Brochner-
Mortensen equation (Fleming et al. 2004). Mean annual GFR decline (mL/min/1.73 
m2/year) was calculated by dividing the difference between two subsequent GFR results 
by the time between the measurements until the last follow-up visit. 
4.2.4 Statistical analyses 
Descriptive numerical data were reported as frequency and percentage, mean and SD, 
median and range, or median and interquartile range (25th–75th percentile), as appropriate. 
Differences in continuous variables between two groups were tested for significance using 
Student’s t-test or Mann-Whitney U-test, as appropriate according to the distribution of 
continuous variables. One-way analysis of variance (ANOVA) or Kruskall-Wallis test was 
applied for comparing three or more groups. Categorical variables were tested with chi-
squared test or Fischer’s exact test. Associations between variables were analyzed with 
Pearson correlation analysis or Spearman’s rank correlation. 
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In Study III, simple linear regression was used for assessing the ability of hypertension, 
relative weight, cholesterol, HDL, LDL, triglycerides, fasting glucose, fasting insulin, 
GHbA1c, or uric acid to predict GFR at 1.5 or 5 years post-RTx or the mean annual GFR 
decline starting at 1.5 or 5 years post-RTx. Hierarchal multiple regression was further 
conducted to assess the ability of triglycerides at 1.5 years post-RTx to predict the 
concomitant GFR, after controlling for the influence of uric acid. 
 
We used SPSS statistics software for Windows (version 17.0 and 19.0; SPSS Inc., 
Chicago, IL, USA) in data analysis. P-values less than 0.05 were considered statistically 
significant throughout the study. 
4.2.5 Ethical considerations 
The study protocol was approved by the Ethics Committee for gynecology and obstetrics, 
pediatrics, and psychiatry of the Helsinki and Uusimaa Hospital District 
(418/13/03/03/2008 and 99/13/03/03/2012). All participating patients and controls, or a 
parent in case of minors, signed a written informed consent form, in accordance with the 
Declaration of Helsinki. 
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5 Results 
The patient characteristics are presented in Table 6. The participation rate was the lowest 
in the cross-sectional male fertility study (II), but according to the hospital records the 
non-responders’ clinical characteristics were comparable to those of the responders, 
except for younger age at the time of the study (data not shown). 
 
 
Table 6. Clinical characteristics according to the studies. 
Study I II III IV 
Number of RTx patients 109 24 210 111 
Male/female ratio, n (%) 72/37 (66/34) 24/0 (100/0) 132/78 (63/37) 73/38 (66/34) 
Disease leading to RTx, n (%)     
CNF 45 (41) 8 (33) 80 (38) 46 (41) 
Urethral valve 15 (14) 7 (29) 25 (12) 16 (14) 
Nephronophthisis 9 (8) 3 (13) 18 (9) 9 (8) 
Polycystic kidney disease 6 (6) 0 18 (9) 9 (8) 
Other 34 (31) 6 (25) 69 (33) 31 (28) 
Age at start of dialysis, years 3.9 (0–15) 8.9 (1–18) NR 2.3 (0–15) 
Age at first RTx, years 4.5 (1–16) 9.6 (2–18) 4.5 (1–18) 4.0 (1–16) 
Re-transplantation, n (%) 9 (8) 6 (25) 17 (8) 0 
Follow-up, years 11.1 (2–19) 18.6 (6–33) 7.0 (2–18) 5.0 (5–10) 
Age at the study, years NA 28.1 (19–42) NA 11.2 (6–21) 
Values are median (range) or number of patients (%). RTx, renal transplantation; CNF, congenital nephrotic 
syndrome of the Finnish type; NR, not recorded; NA, not applicable. 
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5.1 Pubertal development (I) 
5.1.1 Clinical progression 
The mean chronological age was significantly (p < 0.0001 and p = 0.001) ahead of the 
mean bone age at onset of puberty in both boys and girls, respectively (Table 7). During 
puberty, the mean difference between chronological and bone age diminished from the 
mean of 1.7 (range: -0.8–4.2) to 1.1 (range: -1.3–3.3) years in boys and from the mean of 
1.1 (range: -0.8–4.7) to 0.2 (range: -1.8–2.0) years in girls. The boys with delayed onset of 
puberty had undergone RTx on average at older age than the others (10.9 ± 4.5 vs. 6.6 ± 
5.0 years, p = 0.01). One boy and two girls were treated with leuprolein acetate due to 
precocious puberty. 
 
 
Table 7. Characteristics of puberty in RTx recipients. 
Gender Male Female 
Age at onset of puberty, years 12.7 (9.4–16.2) 10.7 (8.9–12.7) 
Delayed onset of puberty, n (%) 12 (22%) 0 
Bone age at onset of puberty, years 11.2 (8.0–13.0) 9.4 (8.0–12.0) 
Length of puberty, years 3.9 (1.3–6.8) 4.7 (2.2–8.4) 
Age at menarche, years NA 12.5 (10.5–14.5) 
Values are mean (range) unless otherwise stated; NA, not applicable. 
 
 
In boys, age at RTx correlated significantly with the age at pubertal onset (Spearman’s 
rank correlation coefficient rs = 0.33, p = 0.01). Similarly, boys transplanted before the age 
of 5 years reached puberty earlier (12.3 ± 1.2 years) than those transplanted at the age of 5 
to 15 years (13.4 ± 1.5 years, p < 0.01). The onset of puberty was similar in short boys and 
in obese boys in comparison with the others (Table 8). MP daily dose, GH therapy, or 
GFR did not correlate with the age at pubertal onset. 
 
In girls, age at RTx correlated significantly with the age at pubertal onset (rs = 0.49, p < 
0.01). The girls having undergone RTx before the age of five years showed a tendency for 
earlier pubertal onset compared to the girls transplanted at the age of 5 to 15 years (10.3 ± 
0.9 vs. 11.0 ± 1.0 years, p = 0.08). Obese girls reached puberty later than the others (p = 
0.04) (Table 8). None of the other factors studied was found to be related to the age at 
pubertal onset. 
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Table 8. Age at the onset of puberty in relation to various associating factors. 
Variable Grouping value Boys Girls 
Height SD score ≥-1.5 SD 12.7 ± 1.5 10.4 ± 1.0 
 <-1.5 SD 13.1 ± 1.4 10.6 ± 1.0 
Relative weight <120% 12.8 ± 1.4 10.2 ± 1.0 
 ≥120% 13.0 ± 1.7  11.1 ± 0.5* 
MP dose <0.10 mg/kg/day 12.6 ± 1.5 10.4 ± 0.8 
 ≥0.10 mg/kg/day 12.7 ± 2.2 10.5 ± 0.8 
GH therapy after RTx No 12.7 ± 1.3 10.4 ± 0.8 
 Yes 13.0 ± 1.6 10.8 ± 1.5 
GFR ≥40 mL/min/1.73 m2 12.5 ± 1.3 10.5 ± 1.1 
 <40 mL/min/1.73 m2 13.3 ± 1.7 10.5 ± 0.8 
Values are mean ± SD. Variables are means of 3 years preceding puberty; SD, standard deviation; Relative 
weight is percentage of the gender- and height-adjusted median; MP, methylprednisolone; GH, growth 
hormone; GFR, glomerular filtration rate. * p < 0.05. 
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5.1.2 Growth and adult height 
Growth continued relatively long and resulted in acceptable FH in both boys and girls 
(Table 9). FH, or the age at reaching it, was not related to age at RTx in either boys or 
girls. 
 
 
Table 9. Characteristics of pubertal growth. 
Variable Male Female 
Age at onset of growth spurt, years 12.4 (8.4–15.7) 9.8 (7.2–13.5) 
Height at onset of growth spurt, cm 141.0 (113.9–155.5) 127.4 (115.5–145.5) 
Age at peak height velocity, years 14.7 (10.2–17.6) 11.6 (9.5–13.6) 
Peak height velocity, cm/year 8.6 (5.0–14.5) 8.4 (6.0–14.0) 
Age at reaching final height, years 18.1 (15.8–24.4) 16.0 (13.9–17.6) 
Final height, cm 168.7 (151.6–181.5) 154.3 (148.1–167.4) 
Final height, standard deviation score -1.2 (-3.8–0.4) -1.7 (-2.7–0.5) 
Values are mean (range). 
 
 
In boys transplanted during adolescence (age 10–15 years) OGS and PHV occurred later 
than in those transplanted earlier (13.6 ± 1.4 vs. 12.1 ± 1.7 years, p = 0.009 and 15.7 ± 1.0 
vs. 14.4 ± 1.8 years, p = 0.03, respectively). Furthermore, the boys in the first group were 
taller at OGS than those in the latter group (145.8 vs. 139.3 cm, p = 0.03). Boys having 
had GH therapy after RTx were significantly older than those without GH therapy at OGS 
(13.0 ± 1.9 vs. 12.0 ± 1.5 years, p = 0.04). 
 
In girls, those transplanted at the age of 5–15 years were only slightly older at OGS than 
the recipients who had been operated younger (10.2 ± 1.6 vs. 9.7 ± 1.7 years, p = 0.49). 
GH therapy after RTx was not related to OGS, PHV, or FH in girls. 
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5.1.3 Reproductive hormones 
Testosterone levels were normal in 51/54 (94%) of the boys (Figure 6). The three males 
with decreased concentration of testosterone had normal levels of FSH and LH. The 
gonadotropins LH and/or FSH were moderately elevated (>10 IU/L) in 4 (7%) boys. 
 
 
 
 
Figure 6. Individual serum concentrations in males (A–D): testosterone (A), inhibin B (B), LH (C), 
and FSH (D), and in females (E–H): estradiol (E), anti-Müllerian hormone (AMH) (F), LH (G), and FSH 
(H). Solid lines are mean ±2 SD in normal Scandinavian population according to Andersson et al., 
Aksglaede et al., and Hagen et al. (Hagen et al. 2010, Andersson et al. 1997, Aksglaede et al. 2009). Filled 
circles indicate patients having had RTx operation after pubertal onset. 
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5.2 Male fertility (II) 
Of the 24 study patients, eight had received cyclophosphamide therapy (median 
cumulative dose: 4.7 g/m2, range: 1.7–9.6 g/m2). The 24 RTx patients were shorter and 
lighter than the 56 controls (median: 170 cm vs. 180 cm, p <0.001 and 73 kg vs. 83 kg, p = 
0.002, respectively) but the median BMIs were comparable (24.3 kg/m2 vs. 25.3 kg/m2, p 
= 0.209, respectively). 
5.2.1 Reproductive endocrine function 
The 24 RTx patients had lower median testosterone (17.5 nmol/L) and calculated free 
testosterone levels (322 pmol/L) than the controls (18.5 nmol/L and 399 pmol/L, p = 0.048 
and p = 0.001, respectively). Correspondingly, the LH levels were higher in RTx men than 
in controls (7.6 vs. 3.3 IU/L, p <0.001). Clinically abnormal testosterone levels (<10 
nmol/L) were detected similarly in RTx patients and controls (13% vs. 4%, p = 0.156). 
Elevated serum LH levels, however, were not found among the controls as opposed to the 
RTx patients (17%, p = 0.007). The cyclophosphamide-treated RTx recipients had higher 
serum LH levels and a tendency for higher serum testosterone levels in comparison with 
those not treated with cyclophosphamide (Figure 7, Table 10). 
 
 
 
 
Figure 7. Testosterone and luteinizing hormone levels in renal transplant patients according to 
history of cyclophosphamide therapy and in healthy controls. The black horizontal lines represent the cut-
off levels of clinical normality and the red lines indicate the median in each subgroup. 
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The median inhibin B and FSH levels were similar among the RTx patients and the 
controls (111 vs. 157 ng/L and 4.4 vs. 3.2 IU/L, p = 0.08 in both). Clinically abnormal 
inhibin B (<100 ng/L) and FSH (>10 IU/L) levels were more frequently found in RTx 
patients than the controls (38% vs. 10%, p = 0.008 and 38% vs. 2%, p <0.001, 
respectively). The inhibin B levels of the cyclophosphamide-treated RTx patients were 
lower than those of the other RTx recipients (Table 10, Figure 8). 
 
 
 
 
Figure 8. Inhibin B and follicle-stimulating hormone levels in renal transplant patients according to 
history of cyclophosphamide therapy and in healthy controls. The black horizontal lines represent the cut-
off levels of clinical normality and the red lines indicate the median in each subgroup. 
 
 
The median adult testis volumes of the RTx recipients were significantly smaller than 
those of the controls (11.4 mL vs. 33.9 mL, p <0.001). Two thirds (n = 16) of the 24 RTx 
patients had a testicular volume below 15 mL. The testicular volumes did not associate 
with prior cyclophosphamide therapy (Table 10). 
 
A significant correlation was found between testicular volume and serum FSH (r = -0.507, 
p = 0.012), LH (r = -0.456, p = 0.025), and inhibin B (r = 0.426, p = 0.038) levels in the 
RTx patients. Testicular size did not correlate with age at dialysis, cumulative dialysis 
duration, age at RTx, time of follow-up, age at the study time, GFR, or cumulative 
cyclophosphamide dose. Furthermore, no significant correlation was found between 
testicular volume and semen volume, semen concentration, total sperm count, motility, 
DNA fragmentation index, testosterone, or free testosterone levels. 
 
Testicular volumes were similar among the RTx patients divided into two subgroups by 
RTx before or after the onset of puberty (n = 17 and n = 7, respectively), or by age at 
dialysis under or above 8 years (n = 12 for both groups). 
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Table 10. Reproductive hormone levels and testicular volumes in study subjects. 
  Renal transplant patients 
Variable 
Controls 
n = 56 
No cyclophosphamide 
n = 16 
Cyclophosphamide 
n = 8 
Luteinizing hormone (IU/L) 3.3 (2.8–4.2) 6.9 (6.0–8.7)c 9.3 (7.6–12.4)c, d 
Testosterone (nmol/L) 18.5 (14.8–23.9) 14.4 (11.6–20.1)a 18.7 (16.1–20.6) 
Free testosterone (pmol/L) 399 (329–481) 312 (279–366)b 323 (282–406)b 
FSH (IU/L) 3.2 (1.9–4.1) 2.7 (1.8–8.2) 12.6 (6.5–17.1)c 
Inhibin B (ng/L) 157 (137–209) 188 (108–262) 50 (18–101)c, d 
SHBG (nmol/L) 33 (24–48) 30 (22–40) 42 (31–53) 
Estradiol (pmol/L) 70 (60–80) 65 (60–80) 75 (53–108) 
Prolactin (mU/L) 216 (173–274) 298 (244–368)c 354 (238–594)a 
Testicular volume (mL) 34 (29–40) 13 (9–18)b 9 (7–15)b 
Values are median (interquartile range).a p < 0.05, b p < 0.01, c p < 0.001 compared to the control group; d p 
< 0.05 compared to the patient group without cyclophosphamide treatment. FSH, follicle-stimulating 
hormone; SHBG, sex hormone-binding globulin. 
5.2.2 Semen quality 
Altogether 18 RTx patients and 54 controls provided a semen sample. The RTx recipients 
had significantly lower median semen volumes, semen concentrations, and total sperm 
counts (2.0 mL, 2.0 106/mL, and 1.3 million, respectively) in comparison with the controls 
(3.0 mL, 49.5 106/mL, and 135.5 million, respectively) (p = 0.003, p < 0.001, and p < 
0.001, respectively). The cyclophosphamide-treated patients also had lower sperm motility 
than the controls (Table 11). 
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In the RTx patients, total sperm count correlated with serum FSH (r = -0.602, p = 0.008), 
inhibin B (r = 0.668, p = 0.002), and cumulative cyclophosphamide dose (r = -0.658, p = 
0.003) (Figure 9). Age at dialysis, age at RTx, timing of RTx (before or after puberty), 
cumulative dialysis duration, follow-up time, age at time of study, or GFR were not found 
to be related to semen quality. In addition, mean testicular volume did not predict total 
sperm count in RTx patients. 
 
 
 
 
Figure 9. Total sperm counts in renal transplant patients according to cumulative cyclophosphamide 
therapy and in healthy controls. The black horizontal lines represent the cut-off levels of clinical normality 
and the red lines indicate the median in each subgroup. 
 
 
The majority of the semen samples of the RTx recipients were abnormal, including nine 
(50%) oligozoospermia (sperm concentration <20 106/mL) and 5 (28%) azoospermia. Of 
the men with azoospermia, 4 men had once been on cyclophosphamide therapy and one 
was currently on sirolimus. Only 4 (22%) of the semen samples had normal sperm count. 
 
Half of the RTx patients were living in a relationship and four men had tried to become a 
parent. Three men, none of whom had ever received cyclophosphamide, had fathered a 
biological child of their own. 
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Table 11. Semen quality in renal transplant patients and healthy controls. 
  Renal transplantation patients 
Variable 
Controls 
n = 56 
No cyclophosphamide 
n = 12 
Cyclophosphamide 
n = 6 
Semen volume (mL) 3.0 (2.5–4.5) 2.1 (1.1–3.9)a 2.0 (1.0–3.3) 
Semen concentration (106/mL) 50 (26–65) 9 (1–24)b 0 (0–1)b, c 
Total sperm count (106) 136 (77–206) 16 (1–47)b 0 (0–3)b, c 
Sperm motility (PR + NP) (%) 65 (58–71) 60 (34–75) 17 (15–)b 
DNA fragmentation index (%) NR 11 (6–33) 34 (34–34) 
Abstinence (days) 3 (2–4) 5 (3–5) 3 (2–4) 
Values are median (interquartile range). Only 2 cyclophosphamide-treated patients had motile sperm. a p < 
0.05, b p < 0.001 compared to the control group. c p < 0.05 compared to the patient group without 
cyclophosphamide treatment. NR, not recorded. 
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5.3 Metabolic risk factors (III) 
5.3.1 Metabolic syndrome 
We recorded the metabolic variables (lipid and glucose metabolism markers and relative 
weight) and BP levels at 1.5, 5, 9, and 13 years post-RTx in order to compile an analysis 
of the patients’ metabolic condition in the long run (Table 12). According to the criteria, 
19% (28/147) and 14% (18/127) of the patients were diagnosed with MS at 1.5 and 5 
years post-RTx, respectively. 
 
Overweight was diagnosed in a fifth of the patients (20–23%) during the post-Tx follow-
up (Table 12). At the same time, the prevalence of obesity (as relative weight >140% of 
the age and height adjusted median) showed a descendent trend (12–2%). 
 
Elevated lipid levels, concerning total cholesterol, LDL, and triglycerides, were frequent 
as up to a third of the patients had hyperlipidemia at control visits (Table 12). None of the 
patients received statins, and during the follow-up the prevalence of abnormal total 
cholesterol levels (>5.0 mmol/L), LDL levels (≥3.0 mmol/L), and triglyceride levels (≥1.7 
mmol/L) varied between 22–39%, 9–31%, and 31–34%, respectively. Low HDL levels 
(<1.0 mmol/L), however, were somewhat scarcer, occurring in 8–13% of the patients. 
 
Glucose levels were relatively stable as abnormal values (fasting glucose ≥5.6 mmol/L or 
insulin >15 mU/L) were observed during the follow-up in 10–20% and 13–26%, 
respectively (Table 12). None of the patients were diagnosed with type 1 diabetes, and 
abnormal GHbA1c values (>6.0%) were also rare. Furthermore, the IGT prevalence 
increased from 18% at 5 years to 40% at 13 years post-RTx, but type 2 diabetes was 
detected in only 3–5% of the patients.  
 
Hypertension, as defined by the indexed office BP levels, was found among the majority 
(87% and 62%) of the patients at 1.5 and 5 years post-RTx, respectively (Table 12). At the 
same time, 60% and 35% of the patients used antihypertensive medication. The systolic 
and diastolic office BP indexes averaged 1.04 and 0.91 (117/66 mmHg) at 1.5 years and 
0.99 and 0.86 (116/66 mmHg) at 5 years post-RTx, respectively. 
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The association between the metabolic factors and GFR was analyzed with respect to 
both concomitant GFR values at 1.5 and 5 years post-RTx and the GFR decline rate 
subsequently. The mean concomitant GFR values of the patients with MS at 1.5 and 5 
years post-RTx tended to be lower than those of the others (Figure 10B and Table 13). In 
simple regression analysis a more pronounced annual GFR decline was found in the 
patients with MS at 1.5 years post-RTx. 
 
Overweight or hypertension did not predict the concomitant or consecutive GFR levels 
during the follow-up (Table 13). Also, the associations between the total cholesterol and 
HDL levels with the different GFR parameters were weak. On the other hand, the LDL 
level at 1.5 years post-RTx associated with the annual GFR decline in the regression 
analysis, but the finding remained sporadic. Hypertriglyceridemia associated with worse 
concomitant GFR levels (Table 13 and Figure 10F). The fasting glucose level associated 
with the concomitant GFR value but overall the GFR levels and the subsequent GFR 
decline rates were similar in patients with normal or aberrant glucose parameters. In 
parallel, the GFR levels and the annual GFR decline rates were similar among patients 
with or without IGT at 5 years. 
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Figure 10. Mean glomerular filtration rates (GFR) during long-term follow-up in two subgroups of 
patients divided at 1.5 years post-transplant according to GFR (A), metabolic syndrome (B), glycosylated 
hemoglobin (GHbA1c) (C), hypertension (D), cholesterol (E), and triglycerides (F). 
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5.4 Blood pressure and graft function (IV) 
5.4.1 Ambulatory blood pressure profiles 
The proportions of recipients in the ABPM categories according to the AHA classification 
were statistically similar between the RTx, HTx, and LTx groups (p = 0.280). Severe 
ambulatory hypertension was fairly common occurring in 38%, 28%, and 23% of the RTx, 
HTx, and LTx recipients, respectively. Indicating poor BP control, normal BP was found 
only in 13%, 21%, and 0% among these groups, respectively. Masked hypertension was 
also common (26–46%), whereas white coat hypertension was very rare (0–2%) among 
the Tx groups. 
 
Data on BP indices and loads according in the Tx patients are presented in Figure 11. The 
BP profiles of the Tx groups were similar. The RTx and HTx patients had higher BP 
indices and loads at nighttime as compared to daytime (p <0.010 in all). Furthermore, the 
HTx patients showed clearly blunted systolic and diastolic dipping averaging only 3.9% 
and 5.3%, respectively. The RTx and LTx groups had thus significantly higher dippings 
than the HTx recipients. 
 
The 45 RTx recipients with and the 66 without antihypertensive medication showed no 
major differences in terms of BP profiles. The systolic BP indices and loads were 
somewhat surprisingly higher in those receiving antihypertensive medication than in the 
others (p = 0.001–0.032). The diastolic nighttime measures, however, were constantly 
higher than the daytime countermeasures regardless of antihypertensive medication (p < 
0.001 in all). The diastolic BP indices, loads, and both the dipping values were similar 
among the patients with or without antihypertensive medication. 
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Figure 11. Systolic and diastolic blood pressure (BP) indices (A and B) and loads (C and D) according 
to time of day in renal transplantation (RTx), heart Tx (HTx), and liver Tx (LTx) patients. The dashed lines 
indicate the thresholds of abnormal values (≥1.0 in index and ≥25% in load). 
5.4.2 Hypertensive BP parameters 
In all the Tx groups, hypertensive BP indices (≥1.0) and BP loads (≥25% or ≥50%) 
occurred markedly more frequently during nighttime than daytime. Eighty-six percent of 
the recipients (76–100% among the subgroups) had at least one BP load measure 
exceeding 25%, whereas 64% of the patients (62–69% among the subgroups) had at least 
one BP load equal to or above 50%. . 
 
The BP indices and loads correlated highly significantly (r = 0.836–0.919; p <0.001 in all 
groups), as shown in Figure 12. Importantly, up to 23–49% of the patients with a BP index 
<1.0 had already the correspondent BP load above 25%, but only 1–4% had the 
correspondent BP load above 50%. Thus, the vast majority (91–97%) of patients with a 
normal BP index had the concomitant BP load between 25–50%.  
 
The lack of normal systolic or diastolic dipping (≥10%) was common in the Tx patients 
(49–83%). RTx patients without a 10% dipping had significantly higher nighttime BP 
indices and loads than those with at least a 10% dipping, but the daytime values were 
comparable between these groups, thus explaining the difference (data not shown). 
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Figure 12. Linear correlations between systolic (A) and diastolic (B) daytime, and systolic (C) and 
diastolic (D) nighttime blood pressure (BP) indices and corresponding BP loads in RTx, HTx, and LTx 
patients. The correlation coefficients are for the study patients as a whole. The dashed lines indicate the 
thresholds of abnormal values (vertical: ≥1.0 in index, lower horizontal: ≥25% in load, and upper 
horizontal: ≥50% in load). 
5.4.3 Relation between blood pressure parameters and clinical variables in 
RTx recipients 
No significant correlations between any of the 10 ABPM parameters (day- or nighttime, 
systolic or diastolic, indices, loads, or BP dippings) and the GFR at the time of the ABPM 
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were found among the RTx patients. This was confirmed by analyses showing that GFR 
below 60 mL/min/1.73 m2 did not predict significantly any of the BP parameters (index, 
load, or dipping) being abnormal. In diastolic dipping, however, 85% of the patients with 
abnormal (<10%) dipping value had a decreased GFR under 60 mL/min/1.73 m2 at the 
time of the ABPM. The proportion was higher compared to that of those with normal 
diastolic BP dipping and decreased GFR (68%, p = 0.04).  
 
Triglycerides correlated with nighttime diastolic BP index (r = 0.215; p = 0.026). No 
significant correlations with any of the ABPM parameters were found among the other 
metabolic factors (total cholesterol, HDL, LDL, and obesity) and age at the time of the 
study (data not shown). 
 
The results showed significant correlations between systolic office BP index and all the 
daytime and nighttime BP indices and loads (r = 0.252–0.578; p <0.001–0.008). We 
verified the usability of the office BP results in predicting BP parameter levels by logistic 
regression analyses and the results were consistent showing that hypertensive office BP do 
predict hypertensive systolic and diastolic BP values both day- and nighttime (data not 
shown). No correlation, however, was found between the office BP and the systolic or 
diastolic dippings (p = 0.117–0.805). 
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6 Discussion 
This thesis reports, in a retrospective and partly cross-sectional manner, the 
endocrinologic and metabolic long-term outcomes in pediatric RTx patients. The results 
showed that female puberty appeared normally after RTx, but in males a delayed pubertal 
timing occurred in a fifth of the patients. This was reflected further as decreased testicular 
function and fertility prospects in young men. Impairment of metabolic factors and 
hypertension occurred frequently, but importantly, the deleterious effect of kidney graft 
function remained moderate in the long run. 
6.1 Puberty 
The pubertal development in pediatric RTx recipients started on average at 12.7 years in 
boys and at 10.7 years in girls. The ages are very similar to those of healthy Finnish 
population (12.2 and 10.8 years) as well as to other Scandinavian populations (Ojajärvi 
1982, Lindgren 1996, Juul et al. 2006). None of the girls had a delayed onset of puberty or 
menarche, whereas 22% of the boys were regarded as late developers. Of the 55 boys only 
two received testosterone therapy due to moderately delayed development, however. The 
mean length of puberty in RTx patients resembled that of healthy Finnish population 
reported by Ojajärvi in 1982 (3.9 vs. 3.4 and 4.7 vs. 4.5 years in boys and girls, 
respectively). 
 
Previous studies have reported of markedly delayed puberty in adolescents with RTx 
(Rees et al. 1988, Van Diemen-Steenvoorde, Donckerwolcke 1988, Nissel et al. 2004, 
Ghanem et al. 2010). Our results are in contradiction to this, but may in part be explained 
by the difference in the patient material. In our center, the CNF children form the largest 
cohort and are transplanted at the age of 1–2 years after a relatively short period of uremic 
phase (peritoneal dialysis lasting 3–12 months from nephrectomy to RTx). In other 
centers, school-aged children with a quite long-lasting uremic state form the largest group 
of RTx patients. The earlier maturation of our adolescents, however, was obvious also in 
those transplanted at school age. Another possible explanation for the difference is that the 
previous studies were conducted on smaller patient cohorts and many of the recipients had 
undergone RTx after pubertal onset. The graft function was not strongly associated with 
the timing of puberty in our patients transplanted prepubertally, opposing interestingly the 
results of studies reporting on renal failure impairing physical maturation (Turenne et al. 
1997, Hokken-Koelega et al. 1994b, Ferraris et al. 1980, Maxwell, Haffner & Rees 1998, 
Harambat, Cochat 2009). We did, however, see a tendency towards later pubertal onset in 
boys with a deteriorating GFR. 
 
GH therapy-induced bone maturation and earlier onset of puberty in children with 
idiopathic short stature was reported in 2002 by Kamp et al. In contradiction, we found no 
difference in pubertal onset between groups with or without GH therapy after RTx. In 
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accordance, our results showed similar timing of pubertal development in subjects with 
short or normal stature and in those who were overweight or normal weight. 
 
The mean age at OGS in our male patients was slightly delayed compared to healthy 
Scandinavian boys (12.4 and 11.8 years, respectively) but in females the timing was 
similar (9.8 years) to that (10.2 years) reported by Aksglaede et al. (2008). In agreement 
with the studies by Nissel et al. (2004) and Schaefer et al. (1990), delayed OGS was 
associated with a late RTx also in our study. In girls, the PHV and age at reaching it 
resembled those reported in the Finnish population, but in boys the average PHV and the 
age at reaching it were blunted and delayed in comparison with their healthy peers 
(Ojajärvi 1982). Importantly, the growth period was somewhat extended, so that the FH 
was reached on average at the age of 18.1 and 16.0 years in males and females, 
respectively. Ojajärvi reported in 1982 that the FH was reached at a mean age of 16.8 and 
15.2 years in boys and girls, respectively. In agreement with a previous report, bone age 
was delayed compared to the chronological age (Englund et al. 2003). 
 
The serum levels of reproductive hormones were normal in the majority of males and only 
four had hypergonadotrophic FSH and/or LH levels (>10 IU/L). The hormone levels of 
females were all normal, suggesting normal ovarian reservoir and prospect of fertility. The 
ovarian function was assessed by anti-Müllerian hormone levels, which do not fluctuate 
significantly during the menstrual cycle (Hagen et al. 2010, Hehenkamp et al. 2006). 
6.2 Male fertility 
Our results suggest that life-long immunosuppressive therapy started after pediatric RTx 
may decrease the fertility of RTx recipients. On the other hand, medical history in terms of 
age at dialysis, duration of dialysis, age at RTx, and follow-up time seem to have a lesser 
impact on reproductive functions. Eighteen RTx patients provided a semen sample, 
including five azoospermic and nine oligozoospermic (low sperm concentration) samples. 
Semen quality in patients who had undergone RTx as a child was significantly worse in 
comparison to the healthy controls. Sperm counts were significantly decreased in those 
with or without a history of cyclophosphamide therapy compared to the values of the 
controls. This is in contrast to earlier studies reporting restoration of gonadal function in 
adult patients after RTx (Ferraris et al. 1980, De Celis, Pedron-Nuevo 1999, Saha et al. 
2002). 
 
Our RTx patient cohort had lower testosterone and calculated free testosterone levels than 
their healthy peers, but the levels were still within the normal reference ranges. The 
Leydig cells secrete testosterone under regulation by the pituitary hormone LH. The 
observed higher serum LH levels, stimulating the maintenance of normal serum 
testosterone level, may indicate subclinical Leydig cell damage as previously described 
among cancer survivors (Kenney et al. 2001). In parallel with other reports, all our 
patients had had a normal pubertal development and had normal sexual characteristics, 
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suggesting that RTx does not disturb testosterone production (Wang et al. 2010, Yadav et 
al. 2008). 
 
Decreased testicular volumes were evident among the RTx recipients regardless of the 
history of cyclophosphamide exposure. The results in semen quality, serum inhibin B 
levels, and adult testicular volumes were even worse in those who had previously received 
cyclophosphamide. The vast majority (80%) of the azoospermic men had a history of 
cyclophosphamide therapy and none of the cyclophosphamide-treated men had fathered a 
child. According to the results, the adult testicular volumes of the RTx men were smaller 
(11 mL) and the total sperm counts were lower (0 million) than those previously reported 
on leukemia survivors treated with similar doses of cyclophosphamide (22 mL and 120 
million, respectively) (Jahnukainen et al. 2011). In contrast to our results, a high 
spermatogenetic recovery rate has also been reported in cyclophosphamide-treated 
patients with nephrotic syndrome without continuous long-term immunosuppressive 
therapy (Bogdanovic, Banicevic & Cvoric 1990). 
 
Testicular volume did not correlate with the semen parameters, age at RTx, or the kidney 
function at the time of the study. The lack of correlation is contradictory to previous 
reports on other infertile cohorts (Bahk et al. 2010, Abramsson, Duchek 1989). A 
testicular volume under 15 mL has been reported to lead to incomplete recovery of normal 
gonadal function and sperm production and as a sign for fertility counseling (Arai et al. 
1998). Our results indicate, however, that adult testicular volume may not predict 
spermatogenetic potential as accurately as described among childhood cancer survivors 
(Jahnukainen et al. 2011). 
6.3 Metabolic consequences 
In our study, the prevalence of MS was 19% and 14% at 1.5 and 5 years after RTx, 
respectively. The numbers are lower compared to those reported previously in pediatric 
patients. Recently, Wilson et al. (2010) reported the results of a multi-center study 
according to which the prevalence of MS was 19% at the time of RTx and 38% at one year 
post-Tx. In a smaller Mexican study, a quarter (8/32) of the patients fulfilled the criteria 
for MS at two years after RTx (Ramirez-Cortes et al. 2009). Glucocorticoids are known to 
predispose Tx recipients to metabolic problems, and in a study by Maduram et al. (2010), 
MS was diagnosed in only 15% of those without a glucocorticoid and in 68% of patients 
receiving prednisone at one year post-RTx. The essential difference between our study and 
the three previous ones is that we focused on the maintenance phase, when the 
immunosuppressive drug dosing was already reduced to a minimum. 
 
Especially during the early maintenance phase post-Tx, overweight is common due to the 
excessive exposure to glucocorticoids. According to previous reports, however, the 
association between obesity and kidney graft function is contradictory in children 
(Mitsnefes, Khoury & McEnery 2002, Kasap et al. 2006, Dart et al. 2010, Boschetti et al. 
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2013). A fifth of our patients were moderately overweight at 1.5 and 5 years after RTx, 
but no clear association with impaired concomitant or future graft function was found. 
This is in contrast to the previous reports on obesity at the time of RTx. Mitsnefes et al. 
reported in 2002 that obese patients at the time of RTx and 1 year thereafter had lower 
GFR levels compared to those who became obese during the first year post-RTx. More 
recently, the opposite finding was reported by Boschetti et al. (2013): those who gained 
weight after the operation had worse graft survival at 36 months. Thus, it seems that 
moderate overweight appearing years after RTx affects kidney graft function less than 
severe obesity during the early postoperative phase. 
 
Hypertension, mainly induced by CNIs and glucocorticoids, has been associated with 
subsequent graft failure (Sorof et al. 1999, Mange et al. 2000, Mitsnefes, Khoury & 
McEnery 2003). Sorof et al. reported in 1999 that hypertension associates with higher 
graft failure rates and the use of antihypertensive medication predicts subsequent graft 
failure in children with RTx. In another study on pediatric patients, systolic hypertension 
at one year post-RTx predicted poor long-term graft survival (Mitsnefes, Khoury & 
McEnery 2003). In line with the results of Krmar et al. (2008) reporting similar GFR 
decline rates in hypertensive and normotensive patients, we did not find a clear association 
between hypertension and later graft function (Krmar, Berg 2008). 
 
Post-Tx diabetes prevalence in children with RTx is reportedly 2–35% (Greenspan et al. 
2002, Kasiske et al. 2003). According to our results, none of the patients developed type 1 
diabetes and type 2 diabetes was diagnosed only in 12 patients (3–5%) during the long-
term follow-up. The low prevalences may be explained by the fact that the majority of the 
patients received CsA instead of tacrolimus. Furthermore, the patients were also on a low-
dose alternate-day MP minimizing the glucocorticoid exposure. In OGTT performed at 5 
years post-RTx, only one of the 6 patients diagnosed with impaired fasting glucose later 
developed type 2 diabetes. The insulin level of ≥75 mU/L in OGTT predicted a more rapid 
subsequent GFR decline, but fasting glucose or insulin levels or GHbA1c did not correlate 
with GFR, in parallel with previous results of both pediatric and adult studies (Gerhardt, 
Grosse Huttmann & Hohage 1999, Prokai et al. 2008, Wiesbauer et al. 2010). IGT was 
commonly (18–40%) found in OGTT but, again, it did not correlate with the GFR levels. 
 
According to our results, decline in GFR could be predicted by hypertriglyceridemia at 1.5 
post-RTx. This is in accordance with the multivariate analysis observations in adult 
patients showing hypertriglyceridemia to be independently associated with impaired renal 
allograft function beyond the first post-Tx year (de Vries et al. 2004). Recently, a register 
study by Bonthuis et al. (2014) confirmed the inverse association between triglyceride 
levels and estimated GFR in pediatric RTx recipients. In our patients, total cholesterol, 
HDL, or LDL did not associate with GFR. While the prevalence of hypercholesterolemia 
(39–22%) and elevated LDL levels (17–4%) decreased during the follow-up, a third of the 
patients remained hypertriglyceridemic. In light of the present study, the importance of 
dietetic guidance of Tx children and adolescents is emphasized. 
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6.4 Blood pressure and graft function 
ABPM is a feasible method to confirm the office BP results suspecting hypertension in 
school-aged children and older subjects. Lack of uniformly accepted criteria for the 
definition of hypertension in respect to ABPM has been a major problem, however. BP 
indices and loads as well as several combinations of these parameters have previously 
been used, complicating the comparison of the results of different studies with each other 
(Seeman et al. 2006, Lingens et al. 1997, Sorof, Poffenbarger & Portman 2000). 
Especially in patients with secondary hypertension, blunted nocturnal BP dipping has been 
regarded as an important indicator for hypertension (Seeman et al. 2005). The AHA 
recommendations helped in the classification but raised some concerns. Some of these 
issues, such as prehypertension, were taken into account in the recent update of this 
classification which also introduced an unclassified patient group with normal or 
hypertensive office BP, normal mean BP but elevated loads (Flynn et al. 2014). 
 
The ABPM profiles of RTx, HTx, and LTx patients resembled each other. To the best of 
our knowledge, no study to date has compared the BP profiles of different Tx recipient 
groups with each other. The predominance of nocturnal hypertension and reduced BP 
dipping was evident in all the Tx groups. This is in line with the results reported 
previously in RTx patients (Morgan et al. 2001). The cause of reduced nocturnal dipping, 
however, has been under debate. The ABPM may interfere with the sleep of a study 
subject, thus, obviously leading to increase in the BP levels during the night. According to 
our results (not shown), patients with essential hypertension undergoing similar BP 
monitoring showed more prominent circadian variation in BP profile than the Tx 
recipients, suggesting that the nocturnal predominance in the Tx patients was not a 
technical bias. There is also some evidence on disturbances in the autonomic BP 
regulation in diabetic population leading to nighttime hypertension, which may also be the 
case in Tx population (Kario et al. 1997). 
 
We found a strong correlation between the BP index and the corresponding BP load. 
Concurrently, our results suggested that the limit of 25% in BP load may emphasize 
hypertension. This is in line with the results by Koshy et al. (2005), which showed that BP 
load of 50% as a cut-off is in better agreement with BP index than the limit of 25%. The 
use of higher cut-off would also be justified by the fact that BP load takes into account 
only the proportion of hypertensive measures and not the magnitude of excess of the 
actual BP measure. Furthermore, in our study only sporadic patients had a BP load below 
25% with the corresponding index being equal to or above one. 
 
In line with the previous results in RTx patients, the majority of our RTx patients were 
considered hypertensive (Giordano et al. 2000, McGlothan et al. 2006, Seeman 2009). 
Hypertension was also often detected in RTx recipients who were on antihypertensive 
medication, in concert with the previous reports. The relatively high prevalence of 
uncontrolled hypertension reflects the fact that ABPM is commonly used as an adjunctive 
method. Previously, when the actual BP levels in most cases have been looking “quite 
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normal” and no strict criteria for interpreting ABPM results have existed (until recently), 
the antihypertensive therapy has rarely been intensified. In addition, nocturnal 
hypertension among the patients treated with antihypertensive drugs is most likely due to 
the fact that the effect of the medication (most often calcium channel blocking agent) 
taken in the morning is insufficient to last the entire day and night. 
 
The ABPM data on other Tx recipients than RTx are relatively scarce (Roche et al. 2008, 
Del Compare et al. 2004). Two previous studies have reported 30% and 50% prevalence 
of hypertension in LTx and HTx patients, respectively (Bayrakci et al. 2012, Walker et al. 
2005). In our study, the frequency of abnormal ABPM in the LTx and HTx patients was 
100% and 76%, respectively, resembling the high prevalence of hypertension observed in 
RTx patients. 
 
The major limitation of this particular study are its retrospective nature and the low 
number of LTx patients. Currently, annual ABPM is routinely performed only in RTx and 
HTx patients in the study center. In LTx patients, ABPM is done only when hypertension 
is suspected. This explains the high prevalence of abnormal ABPM results among the LTx 
patients. In addition, the relatively long time period of 5 to 10 years post-Tx for 
performing the ABPM may introduce a time bias as the graft function decrease over time. 
Eighty-four percent of the measurements were performed 5 to 7 years post-Tx decreasing 
the potential risk for bias, however. The main goal of the present study, however, was to 
compare the ABPM profiles among the different Tx patient groups and to illuminate the 
possible differences in the information provided by the numerous ABPM parameters. 
 
Decreased kidney graft function (defined by measured GFR <60 mL/min/1.73 m2) could 
be predicted by a decreased diastolic BP dipping among RTx patients. We found no 
correlations, however, between the other BP parameters and the GFR or several other 
clinical variables. An association between GFR and hypertension has been previously 
reported in adult Tx patients (Mange et al. 2000, Mitsnefes, Khoury & McEnery 2003, 
Jacobi et al. 2000, Fernandez-Fresnedo et al. 2001). On the other hand, two Swedish 
studies have reported that the velocity of decline in graft function was not affected by 
hypertension compared to normotension, or hypertension during day- or nighttime(Krmar, 
Berg 2008, Cameron et al. 2014). In line with the conclusion of Roche et al. (2008), the 
high incidence of hypertension in all the three Tx groups, however, suggests that the 
immunosuppressive medication (CNIs and MP), as such, is largely responsible for the 
elevated BP levels. 
6.5 Methodology 
The principal strength of this study is that it takes into account all the pediatric patients 
receiving a kidney graft in Finland. All transplantations are performed at the Children’s 
Hospital in Helsinki and the subsequent follow-up of the patients is centralized to the 
study center. In addition, another strength of the study is the exceptionally long follow-up 
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due to the high proportion of CNF children undergoing RTx before the age of two years. 
Our different Tx groups receive very similar immunosuppressive medication (CNI, 
azathioprine or a mycophenolate, and low-dose MP), which makes the comparison of 
these cohorts interesting. 
 
The intensive and robust follow-up protocol allowed virtually complete data collection on 
the national cohort of Tx patients. Thanks to the centralization of follow-up to our 
institution, we were also able, in the case of missing data, to compare the clinical 
information of participants and non-participants. We therefore believe that our studies 
represented well the entire national pediatric RTx recipient cohort. Furthermore, kidney 
function was assessed by direct GFR measurement by means of 51Cr-EDTA clearance. 
Also, the data were collected and assessed by the same investigator, reducing the 
possibility of errors and differences in measuring techniques. 
 
Naturally, this study also has several limitations. The majority of the data were collected 
retrospectively, which limits reaching firm conclusions on some of the associations found. 
In cases of expected results remaining nonsignificant, the small subgroup population size 
may have led to type II statistical errors. For instance in Study II, the higher cumulative 
doses of cyclophosphamide among the tacrolimus-treated patients did not allow us to 
compare the effect of CsA and tacrolimus on semen quality. As for Study II, one 
additional weakness was the relatively small study population and low participation rate, 
which may have caused the lack of correlation, for example, between semen quality and 
GFR. Furthermore, the cohort included three possible outliers, but the re-analysis of the 
data without these patients did not distort the essential findings of the study. 
6.6 Future perspectives 
Because allograft tolerance is not yet in the horizon, immunosuppressive medication will 
continue to be needed in the future. Avoidance of the deleterious effects of 
immunosuppression in parallel with avoiding chronic rejection should thus be pursued. 
Along with the improved long-term patient and graft survival, more precise knowledge is 
also needed on the long-term impact of the underlying disease as well as on general health. 
Despite the improved results in both graft and patient survival, the kidney function 
declines inevitably in pediatric and adult RTx patients by both immunological and non-
immunological mechanisms. The current half-life of kidney graft after pediatric RTx is 
reportedly at its best less than 40 years (Vats et al. 2002). In practice the half-life is far 
less and children transplanted at a very young age, such as those with CNF, need a new 
graft as young adults. Avoidance and treatment of post-Tx problems in childhood is 
therefore important for the success of later therapies. 
 
Further studies on fertility and sexuality of young adults with RTx, especially males, are 
needed. One explanation for the poor semen quality and small testicular volumes may be 
the continuous immunosuppressive therapy. Experimental studies on CsA- and 
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tacrolimus-treated rats have shown various degrees of atrophy of seminiferous tubes and 
problems with spermiation (Masuda et al. 2003, Hisatomi et al. 1996), and therapeutic 
levels of CsA and sirolimus have also been reported to have even stronger toxicity on rat 
spermatogenesis than tacrolimus (Chen et al. 2013). These findings would require 
confirmation with a study on human testes. The cumulative effect of the combination of 
cyclophosphamide therapy and continuous use of other immunosuppressants on 
spermatogenetic recovery would also be of interest. 
 
Studies on metabolic risk factors in RTx children and adolescents are important in at least 
two respects. Firstly, the metabolic factors may have a deleterious effect on the graft 
function and subsequently lead to graft loss, and secondly, they form a long-term risk for 
CVD among RTx patients (Li et al. 2003). The challenge is to find factors that could 
predict the graft and patient outcomes, which justifies larger prospective studies on the 
long-term effect of metabolic factors on graft and patient survival. 
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7 Conclusions 
The main conclusions of this thesis are: 
 
1. Pubertal maturation was quite normal in all female and most male adolescents after 
RTx during childhood or adolescence. Patients having undergone RTx in early 
childhood reached puberty earlier than others. Growth continued relatively long in 
comparison with healthy population resulting in acceptable adult height. 
Reproductive hormone levels were normal in girls and in a great majority of boys. 
 
2. Testicles were small and semen quality was poor in young adult men after 
pediatric RTx. A third of the patients showed signs of hypogonadism. Continuous 
life-long immunosuppressive medication, especially cyclophosphamide therapy, 
may be more deleterious for the testicular endocrine system and sperm production 
than the time with ESRD or deteriorating graft function. The prospect of fertility is 
often decreased, thus sperm cryopreservation, optimally before RTx, should be 
considered for all men who are physically mature enough to produce sperm. 
 
3. Metabolic syndrome and its components (overweight, hypertension, abnormalities 
in lipid and glucose metabolism) associated modestly with the long-term kidney 
graft function beyond the first postoperative year. Triglyceride levels correlated 
with the consequent measured GFR levels, and hypertriglyceridemia at the early 
maintenance phase later on predicted the decrease of graft function. 
 
4. Hypertension was common and the ABPM profiles were similar in RTx, LTx, and 
HTx recipients. The BP load threshold of 50% is a superior cut-off value because 
the cut-off of 25% overstated the high prevalence of hypertension. The BP 
variables provided by the ABPM associated weakly with clinical metabolic factors 
and kidney graft function but, on the other hand, supported each other when 
assessing hypertension. The predominance of nocturnal hypertension emphasizes 
the superiority of ABPM over the office BP measurement as an essential tool for 
long-term follow-up. 
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